Prostaglandins and Bone Metabolism

Principles of Bone Biology: Volume 1-2, Third Edition

Volumn , Issue , 2008, Pages 1235-1271

  Pilbeam, Carol C ^a   Choudhary, Shilpa ^a   Blackwell, Katherine ^a   Raisz, Lawrence G ^a  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882471619     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-373884-4.00072-0     Document Type: Chapter

References (466)

1. S.M. Abraham, T. Lawrence, A. Kleiman, P. Warden, M. Medghalchi, J. Tuckermann, J. Saklatvala and A.R. Clark (2006) Antiinflammatory effects of dexamethasone are partly dependent on induction of dual specificity phosphatase 1. J. Exp. Med. 203 1883-1889.
2. T. Akatsu, N. Takahashi, N. Udagawa, K. Imamura, A. Yamaguchi, K. Sato, N. Nagata and T. Suda (1991) Role of prostaglandins in interleukin-1-induced bone resorption in mice in vitro. J. Bone Miner. Res. 6 183-189.
3. M.P. Akhter, D.M. Cullen, G. Gong and R.R. Recker (2001) Bone biomechanical properties in prostaglandin EP1 and EP2 knockout mice. Bone 29 121-125.
4. M.P. Akhter, D.M. Cullen and L.C. Pan (2006) Bone biomechanical properties in EP4 knockout mice. Calcif. Tissue Int. 78 357-362.
5. T. Akune, S. Ohba, S. Kamekura, M. Yamaguchi, U.I. Chung, N. Kubota, Y. Terauchi, Y. Harada, Y. Azuma, K. Nakamura, T. Kadowaki and H. Kawaguchi (2004) PPARgamma insufficiency enhances osteogenesis through osteoblast formation from bone marrow progenitors. J. Clin. Invest. 113 846-855.
6. I. Alam, S.J. Warden, A.G. Robling and C.H. Turner (2005) Mechanotransduction in bone does not require a functional cyclooxygenase-2 (COX-2) gene. J. Bone Miner. Res. 20 438-446.
7. C.B. Alander and L.G. Raisz (2006) Effects of selective prostaglandins E2 receptor agonists on cultured calvarial murine osteoblastic cells. Prostaglandins Other Lipid Mediat. 81 178-183.
8. I.U. Ali, B.T. Luke, M. Dean and P. Greenwald (2005) Allellic variants in regulatory regions of cyclooxygenase-2: Association with advanced colorectal adenoma. Br. J. Cancer 93 953-959.
9. R.D. Altman, L.L. Latta, R. Keer, K. Renfree, F.J. Hornicek and K. Banovac (1995) Effect of nonsteroidal antiinflammatory drugs on fracture healing: a laboratory study in rats. J. Orthop. Trauma 9 392-400.
10. S. Amano, S. Hanazawa, Y. Kawata, Y. Nakada, Y. Miyata and S. Kitano (1994) Phorbol myristate acetate stimulates osteoclast formation in 1 alpha, 25-dihydroxyvitamin D3-primed mouse embryonic calvarial cells by a prostaglandin-dependent mechanism. J. Bone Miner. Res. 9 465-472.
11. S. An, J. Yang, S.W. So, L. Zeng and E.J. Goetzl (1994) Isoforms of the EP3 subtype of human prostaglandin E2 receptor transduce both intracellular calcium and cAMP signals. Biochemistry 33 14496-14502.
12. D.M. Aronoff, J.A. Oates and O. Boutaud (2006) New insights into the mechanism of action of acetaminophen: Its clinical pharmacologic characteristics reflect its inhibition of the two prostaglandin H2 synthases. Clin. Pharmacol. Ther. 79 9-19.
13. J. Balsinde, M.A. Balboa and E.A. Dennis (1998) Functional coupling between secretory phospholipase A2 and cyclooxygenase-2 and its regulation by cytosolic group IV phospholipase A2. Proc. Natl. Acad. Sci. USA 95 7951-7956.
14. A. Barakat and D. Lieu (2003) Differential responsiveness of vascular endothelial cells to different types of fluid mechanical shear stress. Cell Biochem. Biophys. 38 323-343.
15. P.J. Barnes (2006) Receptor heterodimerization: A new level of cross-talk. J. Clin. Invest. 116 1210-1212.
16. S. Basu, K. Michaelsson, H. Olofsson, S. Johansson and H. Melhus (2001) Association between oxidative stress and bone mineral density. Biochem. Biophys. Res. Commun. 288 275-279.
17. D.C. Bauer, E.S. Orwoll, K.M. Fox, T.M. Vogt, N.E. Lane, M.C. Hochberg, K. Stone and M.C. Nevitt (1996) Aspirin and NSAID use in older women: Effect on bone mineral density and fracture risk. Study of Osteoporotic Fractures Research Group. J. Bone Miner. Res. 11 29-35.
18. L.C. Bell-Parikh, T. Ide, J.A. Lawson, P. McNamara, M. Reilly and G.A. Fitzgerald (2003) Biosynthesis of 15-deoxy-delta12, 14-PGJ2 and the ligation of PPARgamma. J. Clin. Invest. 112 945-955.
19. M. Bergenstock, W. Min, A.M. Simon, C. Sabatino and J.P. O'Connor (2005) A comparison between the effects of acetaminophen and celecoxib on bone fracture healing in rats. J. Orthop. Trauma 19 717-723.
20. A. Bhattacharya, M. Rahman, J. Banu, R.A. Lawrence, H.S. McGuff, I.R. Garrett, M. Fischbach and G. Fernandes (2005) Inhibition of osteoporosis in autoimmune disease prone MRL/Mpj-Fas(lpr) mice by N-3 fatty acids. J. Am. Coll. Nutr. 24 200-209.
21. A. Bhattacharya, M. Rahman, D. Sun and G. Fernandes (2007) Effect of fish oil on bone mineral density in aging C57BL/6 female mice. J. Nutr. Biochem. 18 372-379.
22. C.O. Bingham III., R.J. Fijneman, D.S. Friend, R.P. Goddeau, R.A. Rogers, K.F. Austen and J.P. Arm (1999) Low molecular weight group IIA and group V phospholipase A2 enzymes have different intracellular locations in mouse bone marrow-derived mast cells. J. Biol. Chem. 274 31476-31484.
23. D. Bishop-Bailey and J. Wray (2003) Peroxisome proliferator-activated receptors: A critical review on endogenous pathways for ligand generation. Prostaglandins Other Lipid Mediat. 71 1-22.
24. L.F. Bonewald, M. Flynn, M. Qiao, M.R. Dallas, G.R. Mundy and B.F. Boyce (1997) Mice lacking 5-lipoxygenase have increased cortical bone thickness. Adv. Exp. Med. Biol. 433 299-302.
25. B.F. Boyce, T.B. Aufdemorte, I.R. Garrett, A.J. Yates and G.R. Mundy (1989) Effects of interleukin-1 on bone turnover in normal mice. Endocrinology 125 1142-1150.
26. B.F. Boyce, A.J. Yates and G.R. Mundy (1989) Bolus injections of recombinant human interleukin-1 cause transient hypocalcemia in normal mice. Endocrinology 125 2780-2783.
27. A.R. Brash (1999) Lipoxygenases: Occurrence, functions, catalysis, and acquisition of substrate. J. Biol. Chem. 274 23679-23682.
28. C. Brochhausen, P. Neuland, C.J. Kirkpatrick, R.M. Nusing and G. Klaus (2006) Cyclooxygenases and prostaglandin E2 receptors in growth plate chondrocytes in vitro and in situ—prostaglandin E2 dependent proliferation of growth plate chondrocytes. Arthritis Res. Ther. 8 R78.
29. K.M. Brown, M.M. Saunders, T. Kirsch, H.J. Donahue and J.S. Reid (2004) Effect of COX-2-specific inhibition on fracture-healing in the rat femur. J. Bone Joint Surg. Am. 86-A 116-123.
30. F.G. Buchanan, D. Wang, F. Bargiacchi and R.N. DuBois (2003) Prostaglandin E2 regulates cell migration via the intracellular activation of the epidermal growth factor receptor. J. Biol. Chem. 278 35451-35457.
31. E.H. Burger and J. Klein-Nulend (1999) Mechanotransduction in bone—role of the lacuno-canalicular network. FASEB J. 13 S101-sS112.
32. P.C. Calder (2006) n-3 polyunsaturated fatty acids, inflammation, and inflammatory diseases. Am. J. Clin. Nutr. 83 1505S-s1519S.
33. J.H. Capdevila, J.R. Falck and R.C. Harris (2000) Cytochrome P450 and arachidonic acid bioactivation. Molecular and functional properties of the arachidonate monooxygenase. J. Lipid Res. 41 163-181.
34. L.D. Carbone, F.A. Tylavsky, J.A. Cauley, T.B. Harris, T.F. Lang, D.C. Bauer, K.D. Barrow and S.B. Kritchevsky (2003) Association between bone mineral density and the use of nonsteroidal anti-inflammatory drugs and aspirin: Impact of cyclooxygenase selectivity. J. Bone Miner. Res. 18 1795-1802.
35. M.D. Castellone, H. Teramoto, B.O. Williams, K.M. Druey and J.S. Gutkind (2005) Prostaglandin E2 promotes colon cancer cell growth through a Gs-axin-beta-catenin signaling axis. Science 310 1504-1510.
36. M.D. Castellone, H. Teramoto and J.S. Gutkind (2006) Cyclooxygenase-2 and colorectal cancer chemoprevention: The beta-catenin connection. Cancer Res. 66 11085-11088.
37. J.A. Cauley, R.L. Fullman, K.L. Stone, J.M. Zmuda, D.C. Bauer, E. Barrett-Connor, K. Ensrud, E.M. Lau and E.S. Orwoll (2005) Factors associated with the lumbar spine and proximal femur bone mineral density in older men. Osteoporos. Int. 16 1525-1537.
38. Y.I. Cha and R.N. DuBois (2007) NSAIDs and cancer prevention: Targets downstream of COX-2. Annu. Rev. Med. 58 239-252.
39. N.V. Chandrasekharan, H. Dai, K.L. Roos, N.K. Evanson, J. Tomsik, T.S. Elton and D.L. Simmons (2002) COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: Cloning, structure, and expression. Proc. Natl. Acad. Sci. USA 99 13926-13931.
40. Q. Chen, J.Y. Rho, Z. Fan, S.J. Laulederkind and R. Raghow (2003) Congenital lack of COX-2 affects mechanical and geometric properties of bone in mice. Calcif. Tissue Int. 73 387-392.
41. Q.R. Chen, C. Miyaura, S. Higashi, M. Murakami, I. Kudo, S. Saito, T. Hiraide, Y. Shibasaki and T. Suda (1997) Activation of cytosolic phospholipase A2 by platelet-derived growth factor is essential for cyclooxygenase-2-dependent prostaglandin E2 synthesis in mouse osteoblasts cultured with interleukin-1. J. Biol. Chem. 272 5952-5958.
42. X.S. Chen, U. Kurre, N.A. Jenkins, N.G. Copeland and C.D. Funk (1994) cDNA cloning, expression, mutagenesis of C-terminal isoleucine, genomic structure, and chromosomal localizations of murine 12-lipoxygenases. J. Biol. Chem. 269 13979-13987.
43. M.Z. Cheng, G. Zaman, S.C. Rawlinson, A.A. Pitsillides, R.F. Suswillo and L.E. Lanyon (1997) Enhancement by sex hormones of the osteoregulatory effects of mechanical loading and prostaglandins in explants of rat ulnae. J. Bone Miner. Res. 12 1424-1430.
44. P.P. Cherian, B. Cheng, S. Gu, E. Sprague, L.F. Bonewald and J.X. Jiang (2003) Effects of mechanical strain on the function of Gap junctions in osteocytes are mediated through the prostaglandin EP2 receptor. J. Biol. Chem. 278 43146-43156.
45. D. Chikazu, O. Voznesensky, B. Kream, X. Li, H. Herschman and C. Pilbeam (2001) Parathyroid hormone induces cyclooxygenase-2 in osteoblasts via a composite NFAT/AP-1 binding site. J. Bone Miner. Res. 16(S1), S307.
46. D. Chikazu, X. Li, H. Kawaguchi, Y. Sakuma, O.S. Voznesensky, D.J. Adams, M. Xu, K. Hoshi, V. Katavic, H.R. Herschman, L.G. Raisz and C.C. Pilbeam (2005) Bone morphogenetic protein 2 induces cyclo-oxygenase 2 in osteoblasts via a Cbfa1 binding site: Role in effects of bone morphogenetic protein 2 in vitro and in vivo. J. Bone Miner. Res. 20 1888-1898.
47. W.L. Chou, L.M. Chuang, C.C. Chou, A.H. Wang, J.A. Lawson, G.A. Fitzgerald and Z.F. Chang (2007) Identification of a novel prostaglandin reductase reveals the involvement of prostaglandin E2 catabolism in regulation of peroxisome proliferator-activated receptor gamma activation. J. Biol. Chem. 282 18162-18172.
48. S. Choudhary, S. Wadhwa, L.G. Raisz, C. Alander and C.C. Pilbeam (2003) Extracellular calcium is a potent inducer of cyclo-oxygenase-2 in murine osteoblasts through an ERK signaling pathway. J. Bone Miner. Res. 18 1813-1824.
49. S. Choudhary, P. Halbout, C. Alander, L. Raisz and C. Pilbeam (2007) Strontium ranelate promotes osteoblastic differentiation and mineralization of murine bone marrow stromal cells: Involvement of prostaglandins. J. Bone Miner. Res. 22 1002-1010.
50. J.W. Chow and T.J. Chambers (1994) Indomethacin has distinct early and late actions on bone formation induced by mechanical stimulation. Amer. J. Physiol. 267 E287-eE292.
51. T.A. Cock, J. Back, F. Elefteriou, G. Karsenty, P. Kastner, S. Chan and J. Auwerx (2004) Enhanced bone formation in lipodystrophic PPARgamma (hyp/hyp) mice relocates haematopoiesis to the spleen. EMBO Rep. 5 1007-1012.
52. S.J. Cok and A.R. Morrison (2001) The 3'-untranslated region of murine cyclooxygenase-2 contains multiple regulatory elements that alter message stability and translational efficiency. J. Biol. Chem. 276 23179-23185.
53. R.A. Coleman, W.L. Smith and S. Narumiya (1994) International union of pharmacology classification of prostanoid receptors: Properties, distribution, and structure of the receptors and their subtypes. Pharm. Rev. 46 205-220.
54. D.A. Collins and T.J. Chambers (1991) Effect of prostaglandins E1, E2, and F2 alpha on osteoclast formation in mouse bone marrow cultures. J. Bone Miner. Res. 6 157-164.
55. D.A. Collins and T.J. Chambers (1992) Prostaglandin E2 promotes osteoclast formation in murine hematopoietic cultures through an action on hematopoietic cells. J. Bone Miner. Res. 7 555-561.
56. D.G. Cox, C. Pontes, E. Guino, M. Navarro, A. Osorio, F. Canzian and V. Moreno (2004) Polymorphisms in prostaglandin synthase 2/cyclooxygenase 2 (PTGS2/COX2) and risk of colorectal cancer. Br. J. Cancer 91 339-343.
57. A. Creutzig, W. Lehmacher and M. Elze (2004) Meta-analysis of randomised controlled prostaglandin E1 studies in peripheral arterial occlusive disease stages III and IV. Vasa 33 137-144.
58. N.M. Davies, R.L. Good, K.A. Roupe and J.A. Yanez (2004) Cyclooxygenase-3: Axiom, dogma, anomaly, enigma or splice error?—Not as easy as 1, 2, 3. J. Pharm. Pharm. Sci. 7 217-226.
59. H.W. Deng, F.H. Xu, Q.Y. Huang, H. Shen, H. Deng, T. Conway, Y.J. Liu, Y.Z. Liu, J.L. Li, H.T. Zhang, K.M. Davies and R.R. Recker (2002) A whole-genome linkage scan suggests several genomic regions potentially containing quantitative trait Loci for osteoporosis. J. Clin. Endocrinol. Metab. 87 5151-5159.
60. W.G. Deng, Y. Zhu and K.K. Wu (2004) Role of p300 and PCAF in regulating cyclooxygenase-2 promoter activation by inflammatory mediators. Blood 103 2135-2142.
61. M. Devoto, K. Shimoya, J. Caminis, J. Ott, A. Tenenhouse, M.P. Whyte, L. Sereda, S. Hall, E. Considine, C.J. Williams, G. Tromp, H. Kuivaniemi, L. Ala-Kokko, D.J. Prockop and L.D. Spotila (1998) First-stage autosomal genome screen in extended pedigrees suggests genes predisposing to low bone mineral density on chromosomes 1p, 2p and 4q. Eur. J. Hum. Genet. 6 151-157.
62. D.L. DeWitt and E.A. Meade (1993) Serum and glucocorticoid regulation of gene transcription and expression of the prostaglandin H synthase-1 and prostaglandin H synthase-2 isozymes. Archiv. Biochem. Biophys. 306 94-102.
63. A. Diaz, A.M. Reginato and S.A. Jimenez (1992) Alternative splicing of human prostaglandin G/H synthase mRNA and evidence of differential regulation of the resulting transcripts by transforming growth factor beta 1, interleukin 1 beta, and tumor necrosis factor alpha. J. Biol. Chem. 267 10816-10822.
64. D.S. Dickens, R. Kozielski, P.J. Leavey, C. Timmons and T.P. Cripe (2003) Cyclooxygenase-2 expression does not correlate with outcome in osteosarcoma or rhabdomyosarcoma. J. Pediatr. Hematol. Oncol. 25 282-285.
65. J.R. Dimar, W.A. Ante, Y.P. Zhang and S.D. Glassman (1996) The effects of nonsteroidal anti-inflammatory drugs on posterior spinal fusions in the rat. Spine 21 1870-1876.
66. J.E. Dinchuk, B.D. Car, R.J. Focht, J.J. Johnston, B.D. Jaffee, M.B. Covington, N.R. Contel, V.M. Eng, R.J. Collins and P.M. Czerniak (1995) Renal abnormalities and an altered inflammatory response in mice lacking cyclooxygenase II. Nature 378 406-409.
67. R.T. Dorsam and J.S. Gutkind (2007) G-protein-coupled receptors and cancer. Nat. Rev. Cancer 7 79-94.
68. T.A. Einhorn (2003) Cox-2: Where are we in 2003?—The role of cyclooxygenase-2 in bone repair. Arthritis. Res. Ther. 5 5-7.
69. A.L. Eisinger, L.D. Nadauld, D.N. Shelton, P.W. Peterson, R.A. Phelps, S. Chidester, D.M. Stafforini, S.M. Prescott and D.A. Jones (2006) The adenomatous polyposis coli tumor suppressor gene regulates expression of cyclooxygenase-2 by a mechanism that involves retinoic acid. J. Biol. Chem. 281 20474-20482.
70. A.L. Eisinger, S.M. Prescott, D.A. Jones and D.M. Stafforini (2007) The role of cyclooxygenase-2 and prostaglandins in colon cancer. Prostaglandins Other Lipid Mediat. 82 147-154.
71. K. Endo, K. Sairyo, S. Komatsubara, T. Sasa, H. Egawa, T. Ogawa, D. Yonekura, R. Murakami and N. Yasui (2005) Cyclooxygenase-2 inhibitor delays fracture healing in rats. Acta Orthop. 76 470-474.
72. P.M. Fall, D.T. Breault and L.G. Raisz (1994) Inhibition of collagen synthesis by prostaglandins in the immortalized rat osteoblastic cell line, Py1a: Structure activity relations and signal transduction mechanisms. J. Bone Miner. Res. 9 1935-1943.
73. M. Faure and H.R. Bourne (1995) Differential effects on cAMP on the MAP kinase cascade: Evidence for a cAMP-insensitive step that can bypass Raf-1. Mol. Biol. Cell. 6 1025-1035.
74. O.M. Faye-Petersen, W.H. Johnson, W.A. Carlo, G.L. Hedlund, A.D. Pacifico and H.C. Blair (1996) Prostaglandin E1-induced hyperostosis: Clinicopathologic correlations and possible pathogenetic mechanisms. Pediatr. Pathol. Lab Med. 16 489-507.
75. J.H.M. Feyen and L.G. Raisz (1987) Prostaglandin production by calvariae from sham operated and oophorectomized rats: Effects of 17β-estradiol in vivo. Endocrinology 121 819-821.
76. J.H. Feyen, W.G. van der, P. Moonen, A. Di Bon and P.J. Nijweide (1984) Stimulation of arachidonic acid metabolism in primary cultures of osteoblast-like cells by hormones and drugs. Prostaglandins 28 769-781.
77. G.A. Fitzgerald (2004) Prostaglandins: Modulators of inflammation and cardiovascular risk. J. Clin. Rheumatol. 10 S12-sS17.
78. A.M. Flanagan and T.J. Chambers (1992) Stimulation of bone nodule formation in vitro by prostaglandins E1 and E2. Endocrinology 130 443-448.
79. B.S. Fletcher, D.A. Kujubu, D.M. Perrin and H.R. Herschman (1992) Structure of the mitogen-inducible TIS10 gene and demonstration that the TIS10-encoded protein is a functional prostaglandin G/H synthase. J. Biol. Chem. 267 4338-4344.
80. M.A. Flynn, M. Qiao, C. Garcia, M. Dallas and L.F. Bonewald (1999) Avian osteoclast cells are stimulated to resorb calcified matrices by and possess receptors for leukotriene B4. Calcif. Tissue Int. 64 154-159.
81. L. Forsberg, L. Leeb, S. Thoren, R. Morgenstern and P. Jakobsson (2000) Human glutathione dependent prostaglandin E synthase: Gene structure and regulation. FEBS Lett. 471 78-82.
82. I. Fortier, C. Patry, M. Lora, R. Samadfan and A.J. de Brum-Fernandes (2001) Immunohistochemical localization of the prostacyclin receptor (IP) human bone. Prostaglandins Leukot. Essent. Fatty Acids 65 79-83.
83. I. Fortier, M.A. Gallant, J.A. Hackett, C. Patry and A.J. de Brum-Fernandes (2004) Immunolocalization of the prostaglandin E2 receptor subtypes in human bone tissue: Differences in foetal, adult normal, osteoporotic and pagetic bone. Prostaglandins Leukot. Essent. Fatty Acids 70 431-439.
84. M.R. Forwood (1996) Inducible cyclo-oxygenase (COX-2) mediates the induction of bone formation by mechanical loading in vivo. J. Bone Miner. Res. 11 1688-1693.
85. M.R. Forwood, W.L. Kelly and N.F. Worth (1998) Localisation of prostaglandin endoperoxide H synthase (PGHS)-1 and PGHS-2 in bone following mechanical loading in vivo. Anat. Rec. 252 580-586.
86. R.T. Franceschi, G. Xiao, D. Jiang, R. Gopalakrishnan, S. Yang and E. Reith (2003) Multiple signaling pathways converge on the Cbfa1/Runx2 transcription factor to regulate osteoblast differentiation. Connect. Tissue Res. 44(S1), 109-116.
87. A. Freeman, E. Mallico, O. Voznesensky, A. Bhatt, S. Clark and C. Pilbeam (1999) Transcriptional regulation of prostaglandin G/H synthase-2 in transgenic mice. J. Bone Miner. Res. 14(S1), S472.
88. S. Fries, T. Grosser, T.S. Price, J.A. Lawson, S. Kapoor, S. DeMarco, M.T. Pletcher, T. Wiltshire and G.A. Fitzgerald (2006) Marked interindividual variability in the response to selective inhibitors of cyclooxygenase-2. Gastroenterology 130 55-64.
89. K. Fritsche (2006) Fatty acids as modulators of the immune response. Annu. Rev. Nutr. 26 45-73.
90. K. Fritsche (2007) Important differences exist in the dose-response relationship between diet and immune cell fatty acids in humans and rodents. Li pids 42 961-979.
91. H. Fujino and J.W. Regan (2006) EP4 prostanoid receptor coupling to a pertussis toxin-sensitive inhibitory G protein. Mol. Pharmacol. 69 5-10.
92. H. Fujino, K.A. West and J.W. Regan (2002) Phosphorylation of glycogen synthase kinase-3 and stimulation of T-cell factor signaling following activation of EP2 and EP4 prostanoid receptors by prostaglandin E2. J. Biol. Chem. 277 2614-2619.
93. H. Fujino, W. Xu and J.W. Regan (2003) Prostaglandin E2 induced functional expression of early growth response factor-1 by EP4, but not EP2, prostanoid receptors via the phosphatidylinositol 3-kinase and extracellular signal-regulated kinases. J. Biol. Chem. 278 12151-12156.
94. H. Fujino, S. Salvi and J.W. Regan (2005) Differential regulation of phosphorylation of the cAMP response element-binding protein after activation of EP2 and EP4 prostanoid receptors by prostaglandin E2. Mol. Pharmacol. 68 251-259.
95. T. Fujita, T. Meguro, R. Fukuyama, H. Nakamuta and M. Koida (2002) New signaling pathway for parathyroid hormone and cyclic AMP action on extracellular-regulated kinase and cell proliferation in bone cells. Checkpoint of modulation by cyclic AMP. J. Biol. Chem. 277 22191-22200.
96. K. Fuller and T.J. Chambers (1989) Effect of arachidonic acid metabolites on bone resorption by isolated rat osteoclasts. J. Bone Miner. Res. 4 209-215.
97. A.M. Fulton, X. Ma and N. Kundu (2006) Targeting prostaglandin E EP receptors to inhibit metastasis. Cancer Res. 66 9794-9797.
98. C.D. Funk, X.S. Chen, E.N. Johnson and L. Zhao (2002) Lipoxygenase genes and their targeted disruption. Prostaglandins Other Lipid Mediat. 68–69 303-312.
99. M.A. Gallant, R. Samadfam, J.A. Hackett, J. Antoniou, J.L. Parent and A.J. de Brum-Fernandes (2005) Production of prostaglandin D2 by human osteoblasts and modulation of osteoprotegerin, RANKL, and cellular migration by DP and CRTH2 receptors. J. Bone Miner. Res. 20 672-681.
100. L. Gallicchio, M.A. McSorley, C.J. Newschaffer, L.W. Thuita, H.Y. Huang, S.C. Hoffman and K.J. Helzlsouer (2006) Nonsteroidal antiinflammatory drugs, cyclooxygenase polymorphisms, and the risk of developing breast carcinoma among women with benign breast disease. Cancer 106 1443-1452.
101. W.E. Gallwitz, G.R. Mundy, C.H. Lee, M. Qiao, G.D. Roodman, M. Raftery, S.J. Gaskell and L.F. Bonewald (1993) 5-Lipoxygenase metabolites of arachidonic acid stimulate isolated osteoclasts to resorb calcified matrices. J. Biol. Chem. 268 10087-10094.
102. J. Gao, Q. Ke, H.X. Ma, Y. Wang, Y. Zhou, Z.B. Hu, X.J. Zhai, X.C. Wang, J.W. Qing, W.S. Chen, G.F. Jin, J.Y. Liu, Y.F. Tan, X.R. Wang and H.B. Shen (2007) Functional polymorphisms in the cyclooxygenase 2 (COX-2) gene and risk of breast cancer in a Chinese population. J. Toxicol. Environ. Health A 70 908-915.
103. Q. Gao, M. Xu, P. Zhan, C.B. Alander, C.C. Pilbeam and L.G. Raisz (2007) Demonstration of an anabolic effect of prostaglandin E2 on bone in CD-1 mice. J. Bone Miner. Res. 22(S1), S167.
104. C. Garcia, B.F. Boyce, J. Gilles, M. Dallas, M. Qiao, G.R. Mundy and L.F. Bonewald (1996) Leukotriene B4 stimulates osteoclastic bone resorption both in vitro and in vivo. J. Bone Miner. Res. 11 1619-1627.
105. C. Garcia, M. Qiao, D. Chen, M. Kirchen, W. Gallwitz, G.R. Mundy and L.F. Bonewald (1996) Effects of synthetic peptido-leukotrienes on bone resorption in vitro. J. Bone Miner. Res. 11 521-529.
106. M.J. Gerdin and L.E. Eiden (2007) Regulation of PC12 cell differentiation by cAMP signaling to ERK independent of PKA: Do all the connections add up? Sci. STKE. 2007 e15.
107. L.C. Gerstenfeld, M. Al-Ghawas, Y.M. Alkhiary, D.M. Cullinane, E.A. Krall, J.L. Fitch, E.G. Webb, M.A. Thiede and T.A. Einhorn (2007) Selective and nonselective cyclooxygenase-2 inhibitors and experimental fracture-healing. Reversibility of effects after short-term treatment. J. Bone Joint Surg. Am. 89 114-125.
108. D. Gesty-Palmer, M. Chen, E. Reiter, S. Ahn, C.D. Nelson, S. Wang, A.E. Eckhardt, C.L. Cowan, R.F. Spurney, L.M. Luttrell and R.J. Lefkowitz (2006) Distinct beta-arrestin- and G protein-dependent pathways for parathyroid hormone receptor-stimulated ERK1/2 activation. J. Biol. Chem. 281 10856-10864.
109. G. Girasole, G. Passeri, R.L. Jilka and S.C. Manolagas (1994) Interleukin-11: A new cytokine critical for osteoclast development. J. Clin. Invest. 93 1516-1524.
110. D. Giunta, J. Keller, F.F. Nielsen and B. Melsen (1995) Influence of indomethacin on bone turnover related to orthodontic tooth movement in miniature pigs. Am. J. Orthod. Dentofacial Orthop. 108 361-366.
111. F. Gobeil Jr., A. Vazquez-Tello, A.M. Marrache, M. Bhattacharya, D. Checchin, G. Bkaily, P. Lachapelle, A. Ribeiro-da-Silva and S. Chemtob (2003) Nuclear prostaglandin signaling system: Biogenesis and actions via heptahelical receptors. Can. J. Physiol Pharmacol. 81 196-204.
112. P.F. Gomez, M.H. Pillinger, M. Attur, N. Marjanovic, M. Dave, J. Park, C.O. Bingham III, H. Al-Mussawir and S.B. Abramson (2005) Resolution of inflammation: Prostaglandin E2 dissociates nuclear trafficking of individual NF-kappaB subunits (p65, p50) in stimulated rheumatoid synovial fibroblasts. J. Immunol. 175 6924-6930.
113. F.T. Grall, W.C. Prall, W. Wei, X. Gu, J.Y. Cho, B.K. Choy, L.F. Zerbini, M.S. Inan, S.R. Goldring, E.M. Gravallese, M.B. Goldring, P. Oettgen and T.A. Libermann (2005) The Ets transcription factor ESE-1 mediates induction of the COX-2 gene by LPS in monocytes. FEBS J. 272 1676-1687.
114. L.S. Gregory, W.L. Kelly, R.C. Reid, D.P. Fairlie and M.R. Forwood (2006) Inhibitors of cyclo-oxygenase-2 and secretory phospholipase A2 preserve bone architecture following ovariectomy in adult rats. Bone 39 134-142.
115. S. Grosch, T.J. Maier, S. Schiffmann and G. Geisslinger (2006) Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors. J. Natl. Cancer Inst. 98 736-747.
116. T. Grosser, S. Fries and G.A. Fitzgerald (2006) Biological basis for the cardiovascular consequences of COX-2 inhibition: Therapeutic challenges and opportunities. J. Clin. Invest. 116 4-15.
117. S. Gutierrez, A. Javed, D.K. Tennant, M. van Rees, M. Montecino, G.S. Stein, J.L. Stein and J.B. Lian (2002) CCAAT/enhancer-binding proteins (C/EBP) beta and delta activate osteocalcin gene transcription and synergize with Runx2 at the C/EBP element to regulate bone-specific expression. J. Biol. Chem. 277 1316-1323.
118. Y. Hakeda, M. Shiokawa, H. Mano, T. Kameda, L.G. Raisz and M. Kumegawa (1997) Prostaglandin F2alpha stimulates tyrosine phosphorylation and mitogen-activated protein kinase in osteoblastic MC3T3–E1 cells via protein kinase C activation. Endocrinology 138 1821-1828.
119. Y. Han, S.C. Cowin, M.B. Schaffler and S. Weinbaum (2004) Mechanotransduction and strain amplification in osteocyte cell processes. Proc. Natl. Acad. Sci. USA 101 16689-16694.
120. S.Y. Han, N.K. Lee, K.H. Kim, I.W. Jang, M. Yim, J.H. Kim, W.J. Lee and S.Y. Lee (2005) Transcriptional induction of cyclooxygenase-2 in osteoclast precursors is involved in RANKL-induced osteoclastogenesis. Blood 106 1240-1245.
121. K. Hara, Y. Akiyama, T. Tajima and M. Shiraki (1993) Menatetrenone inhibits bone resorption partly through inhibition of PGE2 synthesis in vitro. J. Bone Miner. Res. 8 535-542.
122. R.E. Harris (2007) Cyclooxygenase-2 (cox-2) and the inflammogenesis of cancer. Subcell. Biochem. 42 93-126.
123. J.R. Harrison, J.A. Lorenzo, H. Kawaguchi, L.G. Raisz and C.C. Pilbeam (1994) Stimulation of prostaglandin E2 production by interleukin-1 and transforming growth factor-α in osteoblastic MC3T3-E1 cells. J. Bone Miner. Res. 9 817-823.
124. J.R. Harrison, P.L. Kelly and C.C. Pilbeam (2000) Involvement of CCAAT enhancer binding protein transcription factors in the regulation of prostaglandin G/H synthase 2 expression by interleukin-1 in osteoblastic MC3T3–E1 cells. J. Bone Miner. Res. 15 1138-1146.
125. A.N. Hata and R.M. Breyer (2004) Pharmacology and signaling of prostaglandin receptors: Multiple roles in inflammation and immune modulation. Pharmacol. Ther. 103 147-166.
126. H.R. Herschman (1994) Regulation of prostaglandin synthase-1 and prostaglandin synthase-2. Cancer Metast. Rev. 13 241-256.
127. H.R. Herschman (2004) Regulation and function of prostaglandin synthase 2/cyclooxygenase II. P. Curtis-Prior (Eds) The Eicosanoids West Sussex, England: John Wiley & Sons, Ltd 43-52.
128. A.K. Hihi, L. Michalik and W. Wahli (2002) PPARs: Transcriptional effectors of fatty acids and their derivatives. Cell Mol. Life Sci. 59 790-798.
129. M.V. Hillsley and J.A. Frangos (1994) Bone tissue engineering: The role of interstitial fluid flow. Biotechnol. Bioeng. 43 573-581.
130. S. Hino, C. Tanji, K.I. Nakayama and A. Kikuchi (2005) Phosphorylation of beta-catenin by cyclic AMP-dependent protein kinase stabilizes beta-catenin through inhibition of its ubiquitination. Mol. Cell Biol. 25 9063-9072.
131. B. Hinz, O. Cheremina and K. Brune (2007) Acetaminophen (paracetamol) is a selective cyclooxygenase-2 inhibitor in man. FASEB J. epub.
132. H. Hirotani, N.A. Tuohy, J.T. Woo, P.H. Stern and N.A. Clipstone (2004) The calcineurin/nuclear factor of activated T cells signaling pathway regulates osteoclastogenesis in RAW264.7 cells. J. Biol. Chem. 279 13984-13992.
133. T. Hla and K. Neilson (1992) Human cyclooxygenase-2 cDNA. Proc. Natl. Acad. Sci. USA 89 7384-7388.
134. M. Hogstrom, P. Nordstrom and A. Nordstrom (2007) n-3 fatty acids are positively associated with peak bone mineral density and bone accrual in healthy men: The NO2 Study. Am. J. Clin. Nutr. 85 803-807.
135. V.R. Holla, J.R. Mann, Q. Shi and R.N. DuBois (2006) Prostaglandin E2 regulates the nuclear receptor NR4A2 in colorectal cancer. J. Biol. Chem. 281 2676-2682.
136. A. Hosono, U. Yamaguchi, A. Makimoto, M. Endo, A. Watanabe, T. Shimoda, M. Kaya, T. Matsumura, H. Sonobe, T. Kusumi, T. Yamaguchi and T. Hasegawa (2007) Utility of immunohistochemical analysis for cyclo-oxygenase 2 in the differential diagnosis of osteoblastoma and osteosarcoma. J. Clin. Pathol. 60 410-414.
137. T.H. Howell, M.K. Jeffcoat, P. Goldhaber, M.S. Reddy, M.L. Kaplan, H.G. Johnson, C.M. Hall and R.C. Williams (1991) Inhibition of alveolar bone loss in beagles with the NSAID naproxen. J. Periodontal. Res. 26 498-501.
138. H. Huang, S. Choudhary, L. Raisz and C. Pilbeam (2007) Continuous treatment with PTH is anabolic inc cultured osteoblasts from COX-2 knockout mice. J. Bone Miner. Res. 22(S1), S371.
139. M. Hughes-Fulford (2004) Signal transduction and mechanical stress. Sci. STKE 2004 RE12.
140. M.M. Hurley, P. Fall, J.R. Harrison, D.N. Petersen, B.E. Kream and L.G. Raisz (1989) Effects of tranforming growth factor α and interleukin-1 on DNA synthesis, collagen synthesis, procollagen mRNA levels, and prostaglandin E2 production in cultured fetal rat calvaria. J. Bone Miner. Res. 4 731-736.
141. M.M. Hurley, S.K. Lee, L.G. Raisz, P. Bernecker and J. Lorenzo (1998) Basic fibroblast growth factor induces osteoclast formation in murine bone marrow cultures. Bone 22 309-316.
142. S. Ichikawa, D.L. Koller, M.L. Johnson, D. Lai, X. Xuei, H.J. Edenberg, R.F. Klein, E.S. Orwoll, S.L. Hui, T.M. Foroud, M. Peacock and M.J. Econs (2006) Human ALOX12, but not ALOX15, is associated with BMD in white men and women. J. Bone Miner. Res. 21 556-564.
143. T. Ide, K. Egan, L.C. Bell-Parikh and G.A. Fitzgerald (2003) Activation of nuclear receptors by prostaglandins. Thromb. Res. 110 311-315.
144. K. Igarashi, J.T. Woo and P.H. Stern (2002) Effects of a selective cyclooxygenase-2 inhibitor, celecoxib, on bone resorption and osteoclastogenesis in vitro. Biochem. Pharmacol. 63 523-532.
145. F. Ikeda, R. Nishimura, T. Matsubara, S. Tanaka, J. Inoue, S.V. Reddy, K. Hata, K. Yamashita, T. Hiraga, T. Watanabe, T. Kukita, K. Yoshioka, A. Rao and T. Yoneda (2004) Critical roles of c-Jun signaling in regulation of NFAT family and RANKL-regulated osteoclast differentiation. J. Clin. Invest. 114 475-484.
146. M. Inada, C. Matsumoto, S. Uematsu, S. Akira and C. Miyaura (2006) Membrane-bound prostaglandin E synthase-1-mediated prostaglandin E2 production by osteoblast plays a critical role in lipopolysaccharide-induced bone loss associated with inflammation. J. Immunol. 177 1879-1885.
147. H. Inoue, N. Tanaka and C. Uchiyama (1995) Parathyroid hormone increases the number of tartrate-resistant acid phosphatase-positive cells through prostaglandin E2 synthesis in adherent cell culture of neonatal rat bones. Endocrinology 136 3648-3656.
148. K. Ishikawa, T. Ohta, M. Hirano, K. Yoshimoto, S. Tanaka and S. Inoue (2000) Relation of lifestyle factors to metacarpal bone mineral density was different depending on menstrual condition and years since menopause in Japanese women. Eur. J. Clin. Nutr. 54 9-13.
149. K.N. Ivey and D. Srivastava (2006) The paradoxical patent ductus arteriosus. J. Clin. Invest. 116 2863-2865.
150. S.A. Jacobsson, K. Djerf, I. Ivarsson and O. Wahlstrom (1994) Effect of diclofenac on fixation of hydroxyapatite-coated implants. An experimental study. J. Bone Joint Surg. Br. 76 831-833.
151. P.J. Jakobsson, S. Thoren, R. Morgenstern and B. Samuelsson (1999) Identification of human prostaglandin E synthase: a microsomal, glutathione-dependent, inducible enzyme, constituting a potential novel drug target. Proc. Natl. Acad. Sci. USA 96 7220-7225.
152. T.J. Jang, H.J. Kang, J.R. Kim and C.H. Yang (2004) Nonsteroidal anti-inflammatory drug activated gene (NAG-1) expression is closely related to death receptor-4 and -5 induction, which may explain sulindac sulfide-induced gastric cancer cell apoptosis. Carcinogenesis 10 1848-1853.
153. W.S. Jee and Y.F. Ma (1997) The in vivo anabolic actions of prostaglandins in bone. Bone 21 297-304.
154. M.K. Jeffcoat, M.S. Reddy, L.W. Moreland and W.J. Koopman (1993) Effects of nonsteroidal antiinflammatory drugs on bone loss in chronic inflammatory disease. Ann. N. Y. Acad. Sci. 696 292-302.
155. E.J. Jeon, K.Y. Lee, N.S. Choi, M.H. Lee, H.N. Kim, Y.H. Jin, H.M. Ryoo, J.Y. Choi, M. Yoshida, N. Nishino, B.C. Oh, K.S. Lee, Y.H. Lee and S.C. Bae (2006) Bone morphogenetic protein-2 stimulates Runx2 acetylation. J. Biol. Chem. 281 16502-16511.
156. J. Jiang, H.S. Lv, J.H. Lin, D.F. Jiang and Z.K. Chen (2005) LTB4 can directly stimulate human osteoclast formation from PBMC independent of RANKL. Artif. Cells Blood Substit. Immobil. Biotechnol. 33 391-403.
157. M. Joo, G.Y. Park, J.G. Wright, T.S. Blackwell, M.L. Atchison and J.W. Christman (2004) Transcriptional regulation of the cyclooxygenase-2 gene in macrophages by PU.1. J. Biol. Chem. 279 6658-6665.
158. D. Kamei, K. Yamakawa, Y. Takegoshi, M. Mikami-Nakanishi, Y. Nakatani, S. Oh-ishi, H. Yasui, Y. Azuma, N. Hirasawa, K. Ohuchi, H. Kawaguchi, Y. Ishikawa, T. Ishii, S. Uematsu, S. Akira, M. Murakami and I. Kudo (2004) Reduced pain hypersensitivity and inflammation in mice lacking microsomal prostaglandin e synthase-1. J. Biol. Chem. 279 33684-33695.
159. H. Kaneki, I. Takasugi, M. Fujieda, M. Kiriu, S. Mizuochi and H. Ide (1999) Prostaglandin E2 stimulates the formation of mineralized bone nodules by a cAMP-independent mechanism in the culture of adult rat calvarial osteoblasts. J. Cell Biochem. 73 36-48.
160. H. Kaneko, M. Mehrotra, C. Alander, U. Lerner, C. Pilbeam and L. Raisz (2007) Effects of prostaglandin E2 and lipopolysaccharide on osteoclastogenesis in RAW 264.7 cells. Prostaglandins Leukot. Essent. Fatty Acids epub.
161. Y.J. Kang, B.A. Wingerd, T. Arakawa and W.L. Smith (2006) Cyclooxygenase-2 gene transcription in a macrophage model of inflammation. J. Immunol. 177 8111-8122.
162. Y.J. Kang, U.R. Mbonye, C.J. Delong, M. Wada and W.L. Smith (2007) Regulation of intracellular cyclooxygenase levels by gene transcription and protein degradation. Prog. Lipid Res. 46 108-125.
163. S. Kasugai, S. Oida, T. Iimura, N. Arai, K. Takeda, K. Ohya and S. Sasaki (1995) Expression of prostaglandin E receptor subtypes in bone: expression of EP2 in bone development. Bone 17 1-4.
164. H. Kawaguchi, L.G. Raisz, O.S. Voznesensky, C.B. Alander, Y. Hakeda and C.C. Pilbeam (1994) Regulation of the two prostaglandin G/H synthases by parathyroid hormone, interleukin-1, cortisol and prostaglandin E2 in cultured neonatal mouse calvariae. Endocrinology 135 1157-1164.
165. H. Kawaguchi, C. Pilbeam, S. Vargas, E. Morse, J. Lorenzo and L.G. Raisz (1995) Ovariectomy enhances and estrogen replacement inhibits the activity of marrow factors which stimulate prostaglandin production in cultured mouse calvariae. J. Clin. Invest. 96 539-548.
166. H. Kawaguchi, C.C. Pilbeam, G. Gronowicz, C. Abreu, B.S. Fletcher, H.R. Herschman, L.G. Raisz and M.M. Hurley (1995) Transcriptional induction of prostaglandin G/H synthase-2 by basic fibroblast growth factor. J. Clin. Invest. 96 923-930.
167. H. Kawaguchi, K. Nemoto, L.G. Raisz, J.R. Harrison, O.S. Voznesensky, C.B. Alander and C.C. Pilbeam (1996) Interleukin-4 inhibits prostaglandin G/H synthase-2 and cytosolic phospholipase A2 induction in neonatal mouse parietal bone cultures. J. Bone Miner. Res. 11 358-366.
168. H.Z. Ke, D.T. Crawford, H. Qi, H.A. Simmons, T.A. Owen, V.M. Paralkar, M. Li, B. Lu, W.A. Grasser, K.O. Cameron, B.A. Lefker, P. Silva-Jardine, D.O. Scott, Q. Zhang, X.Y. Tian, W.S. Jee, T.A. Brown and D.D. Thompson (2006) A nonprostanoid EP4 receptor selective prostaglandin E2 agonist restores bone mass and strength in aged, ovariectomized rats. J. Bone Miner. Res. 21 565-575.
169. M.J. Kehoe, S.M. Cohen, K. Zarrinnia and A. Cowan (1996) The effect of acetaminophen, ibuprofen, and misoprostol on prostaglandin E2 synthesis and the degree and rate of orthodontic tooth movement. Angle Orthod. 66 339-349.
170. S. Keila, S. Pitaru, A. Grosskopf and M. Weinreb (1994) Bone marrow from mechanically unloaded rat bones expresses reduced osteogenic capacity in vitro. J. Bone Miner. Res. 9 321-327.
171. J. Keller, A. Klamer, B. Bak and P. Suder (1993) Effect of local prostaglandin E2 on fracture callus in rabbits. Acta Orthop. Scand. 64 59-63.
172. B.P. Kennedy, P. Payette, J. Mudgett, P. Vadas, W. Pruzanski, M. Kwan, C. Tang, D.E. Rancourt and W.A. Cromlish (1995) A natural disruption of the secretory group II phospholipase A2 gene in inbred mouse strains. J. Biol. Chem. 270 22378-22385.
173. L. Kesavalu, B. Vasudevan, B. Raghu, E. Browning, D. Dawson, J.M. Novak, M.C. Correll, M.J. Steffen, A. Bhattacharya, G. Fernandes and J.L. Ebersole (2006) Omega-3 fatty acid effect on alveolar bone loss in rats. J. Dent. Res. 85 648-652.
174. H. Kienapfel, M. Koller, A. Wust, C. Sprey, H. Merte, R. Engenhart-Cabillic and P. Griss (1999) Prevention of heterotopic bone formation after total hip arthroplasty: a prospective randomised study comparing postoperative radiation therapy with indomethacin medication. Arch. Orthop. Trauma Surg. 119 296-302.
175. D.B. Kimmel, T. Coble and N. Lane (1992) Long-term effect of naproxen on cancellous bone in ovariectomized rats. Bone 13 167-172.
176. B. Kis, J.A. Snipes and D.W. Busija (2005) Acetaminophen and the cyclooxygenase-3 puzzle: Sorting out facts, fictions, and uncertainties. J. Pharmacol. Exp. Ther. 315 1-7.
177. B. Kis, J.A. Snipes, T. Gaspar, G. Lenzser, C.D. Tulbert and D.W. Busija (2006) Cloning of cyclooxygenase-1b (putative COX-3) in mouse. Inflamm. Res. 55 274-278.
178. K. Klaushofer, F. Varga, H. Glantschnig, N. Fratzl-Zelman, E. Czerwenka, H.J. Leis, K. Koller and M. Peterlik (1995) The regulatory role of thyroid hormones in bone cell growth and differentiation. J. Nutr. 125 1996S-s2003S.
179. D.C. Klein and L.G. Raisz (1970) Prostaglandins: Stimulation of bone resorption in tissue culture. Endocrinology 86 1436-1440.
180. R.F. Klein, J. Allard, Z. Avnur, T. Nikolcheva, D. Rotstein, A.S. Carlos, M. Shea, R.V. Waters, J.K. Belknap, G. Peltz and E.S. Orwoll (2004) Regulation of bone mass in mice by the lipoxygenase gene Alox15. Science 303 229-232.
181. J. Klein-Nulend, C.C. Pilbeam, J.R. Harrison, P.M. Fall and L.G. Raisz (1991) Mechanism of regulation of prostaglandin production by parathyroid hormone, interleukin-1, and cortisol in cultured mouse parietal bones. Endocrinology 128 2503-2510.
182. J. Klein-Nulend, C.C. Pilbeam and L.G. Raisz (1991) Effect of 1, 25-dihydroxyvitamin D3 on prostaglandin E2 production in cultured mouse parietal bones. J. Bone Miner. Res. 6 1339-1345.
183. J. Klein-Nulend, E.H. Burger, C.M. Semeins, L.G. Raisz and C.C. Pilbeam (1997) Pulsating fluid flow stimulates prostaglandin release and inducible prostaglandin G/H synthase mRNA expression in primary mouse bone cells. J. Bone Miner. Res. 12 45-51.
184. T. Knosel, Y. Yu, U. Stein, H. Schwabe, K. Schluns, P.M. Schlag, M. Dietel and I. Petersen (2004) Overexpression of cyclooxygenase-2 correlates with chromosomal gain at the cyclooxygenase-2 locus and decreased patient survival in advanced colorectal carcinomas. Dis. Colon Rectum. 47 70-77.
185. T.M. Knothe, U. Knothe and P. Niederer (1998) Experimental elucidation of mechanical load-induced fluid flow and its potential role in bone metabolism and functional adaptation. Am. J. Med. Sci. 316 189-195.
186. T. Kobayashi and S. Narumiya (2002) Function of prostanoid receptors: Studies on knockout mice. Prostaglandins Other Lipid Mediat. 68–69 557-573.
187. Y. Kobayashi, T. Mizoguchi, I. Take, S. Kurihara, N. Udagawa and N. Takahashi (2005) Prostaglandin E2 enhances osteoclastic differentiation of precursor cells through protein kinase A-dependent phosphorylation of TAK1. J. Biol. Chem. 280 11395-11403.
188. Y. Kobayashi, I. Take, T. Yamashita, T. Mizoguchi, T. Ninomiya, T. Hattori, S. Kurihara, H. Ozawa, N. Udagawa and N. Takahashi (2005) Prostaglandin E2 receptors EP2 and EP4 are down-regulated during differentiation of mouse osteoclasts from their precursors. J. Biol. Chem. 280 24035-24042.
189. T. Koga, Y. Matsui, M. Asagiri, T. Kodama, C.B. de, K. Nakashima and H. Takayanagi (2005) NFAT and Osterix cooperatively regulate bone formation. Nat. Med. 11 880-885.
190. G. Kong, H.T. Kim, K. Wu, D. DeNardo, S.G. Hilsenbeck, X.C. Xu, W.W. Lamph, R. Bissonnette, A.J. Dannenberg and P.H. Brown (2005) The retinoid X receptor-selective retinoid, LGD1069, down-regulates cyclooxygenase-2 expression in human breast cells through transcription factor crosstalk: Implications for molecular-based chemoprevention. Cancer Res. 65 3462-3469.
191. M. Korotkova, M. Westman, K.R. Gheorghe, K.E. af, C. Trollmo, A.K. Ulfgren, L. Klareskog and P.J. Jakobsson (2005) Effects of antirheumatic treatments on the prostaglandin E2 biosynthetic pathway. Arthritis Rheum. 52 3439-3447.
192. E. Kostenis and T. Ulven (2006) Emerging roles of DP and CRTH2 in allergic inflammation. Trends Mol. Med. 12 148-158.
193. S. Kotake, N. Udagawa, N. Takahashi, K. Matsuzaki, K. Itoh, S. Ishiyama, S. Saito, K. Inoue, N. Kamatani, M.T. Gillespie, T.J. Martin and T. Suda (1999) IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J. Clin. Invest. 103 1345-1352.
194. S.A. Kraemer, E.A. Meade and D.L. DeWitt (1992) Prostaglandin endoperoxide synthase gene structure: Identification of the transcriptional start site and 5'-flanking regulatory sequences. Archiv. Biochem. Biophys. 293 391-400.
195. D.A. Kujubu, B.S. Fletcher, B.C. Varnum, R.W. Lim and H.R. Herschman (1991) TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue. J. Biol. Chem. 266 12866-12872.
196. R.J. Kulmacz, W.A. van der Donk and A.L. Tsai (2003) Comparison of the properties of prostaglandin H synthase-1 and -2. Prog. Lipid Res. 42 377-404.
197. H. Kuwata, H. Sawada, M. Murakami and I. Kudo (1999) Role of type IIA secretory phospholipase A2 in arachidonic acid metabolism. Adv. Exp. Med Biol. 469 183-188.
198. C.S. Lader and A.M. Flanagan (1998) Prostaglandin E2, interleukin 1alpha, and tumor necrosis factor-alpha increase human osteoclast formation and bone resorption in vitro. Endocrinology 139 3157-3164.
199. N. Lane, T. Coble and D.B. Kimmel (1990) Effect of naproxen on cancellous bone in ovariectomized rats. J. Bone Miner. Res. 5 1029-1035.
200. N.E. Lane, D.C. Bauer, M.C. Nevitt, A.R. Pressman and S.R. Cummings (1997) Aspirin and nonsteroidal antiinflammatory drug use in elderly women: Effects on a marker of bone resorption. The Study of Osteoporotic Fractures Research Group. J. Rheumatol. 24 1132-1136.
201. H. Langberg, R. Boushel, D. Skovgaard, N. Risum and M. Kjaer (2003) Cyclo-oxygenase-2 mediated prostaglandin release regulates blood flow in connective tissue during mechanical loading in humans. J. Physiol. 551 683-689.
202. R. Langenbach, S.G. Morham, H.F. Tiano, C.D. Loftin, B.I. Ghanayem, P.C. Chulada, J.F. Mahler, C.A. Lee, E.H. Goulding and K.D. Kluckman (1995) Prostaglandin synthase 1 gene disruption in mice reduces arachidonic acid-induced inflammation and indomethacin-induced gastric ulceration. Cell 83 483-492.
203. R. Langenbach, C. Loftin, C. Lee and H. Tiano (1999) Cyclooxygenase knockout mice: Models for elucidating isoform-specific functions. Biochem. Pharmacol. 58 1237-1246.
204. R. Langenbach, C.D. Loftin, C. Lee and H. Tiano (1999) Cyclooxygenase-deficient mice. A summary of their characteristics and susceptibilities to inflammation and carcinogenesis. Ann. N. Y. Acad. Sci. 889 52-61.
205. L.E. Lanyon (1992) Control of bone architecture by functional load bearing. J. Bone Miner. Res. 7 S369-sS375.
206. M. Lasa, M. Brook, J. Saklatvala and A.R. Clark (2001) Dexamethasone destabilizes cyclooxygenase 2 mRNA by inhibiting mitogen-activated protein kinase p38. Mol. Cell Biol. 21 771-780.
207. S.J. Laulederkind, B.M. Wall, L.R. Ballou and R. Raghow (2002) Renal pathology resulting from PGHS-2 gene ablation in DBA/B6 mice. Prostaglandins Other Lipid Mediat. 70 161-168.
208. B. Lecka-Czernik and L.J. Suva (2006) Resolving the two “bony” faces of PPAR-gamma. PPAR Res. 2006 27489.
209. M.K. Lee, H. Choi, M. Gil and V.M. Nikodem (2006) Regulation of osteoblast differentiation by Nurr1 in MC3T3-E1 cell line and mouse calvarial osteoblasts. J. Cell Biochem. 99 986-994.
210. E.J. Lee, E.M. Choi, S.R. Kim, J.H. Park, H. Kim, K.S. Ha, Y.M. Kim, S.S. Kim, M. Choe, J.I. Kim and J.A. Han (2007) Cyclooxygenase-2 promotes cell proliferation, migration and invasion in U2OS human osteosarcoma cells. Exp. Mol. Med. 39 469-476.
211. U.H. Lerner, M. Ransjo and O. Ljunggren (1987) Prostaglandin E2 causes a transient inhibition of mineral mobilization, matrix degradation, and lysosomal enzyme release from mouse calvarial bones in vitro. Calcif. Tissue Int. 40 323-331.
212. X. Li, Y. Okada, C.C. Pilbeam, J.A. Lorenzo, C.R. Kennedy, R.M. Breyer and L.G. Raisz (2000) Knockout of the murine prostaglandin EP2 receptor impairs osteoclastogenesis in vitro. Endocrinology 141 2054-2061.
213. M. Li, S. Song, S.M. Lippman, X.K. Zhang, X. Liu, R. Lotan and X.C. Xu (2002) Induction of retinoic acid receptor-beta suppresses cyclooxygenase-2 expression in esophageal cancer cells. Oncogene 21 411-418.
214. M. Li, H.Z. Ke, H. Qi, D.R. Healy, Y. Li, D.T. Crawford, V.M. Paralkar, T.A. Owen, K.O. Cameron, B.A. Lefker, T.A. Brown and D.D. Thompson (2003) A novel, non-prostanoid EP2 receptor-selective prostaglandin E2 agonist stimulates local bone formation and enhances fracture healing. J. Bone Miner. Res. 18 2033-2042.
215. M. Li, D.R. Healy, Y. Li, H.A. Simmons, D.T. Crawford, H.Z. Ke, L.C. Pan, T.A. Brown and D.D. Thompson (2005) Osteopenia and impaired fracture healing in aged EP4 receptor knockout mice. Bone 37 46-54.
216. L. Li, A.R. Pettit, L.S. Gregory and M.R. Forwood (2006) Regulation of bone biology by prostaglandin endoperoxide H synthases (PGHS): a rose by any other name. Cytokine Growth Factor Rev. 17 203-216.
217. M. Li, L.C. Pan, H.A. Simmons, Y. Li, D.R. Healy, B.S. Robinson, H.Z. Ke and T.A. Brown (2006) Surface-specific effects of a PPARgamma agonist, darglitazone, on bone in mice. Bone 39 796-806.
218. Y. Li, S. Asuri, J.F. Rebhun, A.F. Castro, N.C. Paranavitana and L.A. Quilliam (2006) The RAP1 guanine nucleotide exchange factor Epac2 couples cyclic AMP and Ras signals at the plasma membrane. J. Biol. Chem. 281 2506-2514.
219. M. Li, D.D. Thompson and V.M. Paralkar (2007) Prostaglandin E2 receptors in bone formation. Int. Orthop. 31 767-772.
220. H. Lim and S.K. Dey (2002) A novel pathway of prostacyclin signaling—hanging out with nuclear receptors. Endocrinology 143 3207-3210.
221. H. Lim, B.C. Paria, S.K. Das, J.E. Dinchuk, R. Langenbach, J.M. Trzaskos and S.K. Dey (1997) Multiple female reproductive failures in cyclooxygenase 2–deficient mice. Cell 91 197-208.
222. B.Y. Lin, W.S.S. Jee, Y.F. Ma, H.Z. Ke, D.B. Kimmel and X.J. Li (1994) Effects of prostaglandin E2 and risedronate administration on cancellous bone in older female rats. Bone 15 489-496.
223. O. Ljunggren, H. Johansson, S. Ljunghall and U.H. Lerner (1991) Thrombin increases cytoplasmic Ca2+ and stimulates formation of prostaglandin-E2 in the osteoblastic cell line MC3T3–E1. Bone Miner. 12 81-90.
224. Ö. Ljunggren, R. Vavrek, J.M. Stewart and U.H. Lerner (1991) Bradykinin-induced burst of prostaglandin formation in osteoblasts is mediated via B2 bradykinin receptors. J. Bone Miner. Res. 6 807-816.
225. C.D. Loftin, D.B. Trivedi, H.F. Tiano, J.A. Clark, C.A. Lee, J.A. Epstein, S.G. Morham, M.D. Breyer, M. Nguyen, B.M. Hawkins, J.L. Goulet, O. Smithies, B.H. Koller and R. Langenbach (2001) Failure of ductus arteriosus closure and remodeling in neonatal mice deficient in cyclooxygenase-1 and cyclooxygenase-2. Proc. Natl. Acad. Sci. USA 98 1059-1064.
226. X. Ma, N. Kundu, S. Rifat, T. Walser and A.M. Fulton (2006) Prostaglandin E receptor EP4 antagonism inhibits breast cancer metastasis. Cancer Res. 66 2923-2927.
227. F. Macian (2005) NFAT proteins: Key regulators of T-cell development and function. Nat. Rev. Immunol. 5 472-484.
228. F. Macian, C. Garcia-Rodriguez and A. Rao (2000) Gene expression elicited by NFAT in the presence or absence of cooperative recruitment of Fos and Jun. EMBO J. 19 4783-4795.
229. F. Macian, C. Lopez-Rodriguez and A. Rao (2001) Partners in transcription: NFAT and AP-1. Oncogene 20 2476-2489.
230. M. MacPhee, K.P. Chepenik, R.A. Liddell, K.K. Nelson, L.D. Siracusa and A.M. Buchberg (1995) The secretory phospholipase A2 gene is a candidate for the Mom1 locus, a major modifier of ApcMin-induced intestinal neoplasia. Cell 81 957-966.
231. H. Mano, C. Kimura, Y. Fujisawa, T. Kameda, M. Watanabe-Mano, H. Kaneko, T. Kaneda, Y. Hakeda and M. Kumegawa (2000) Cloning and function of rabbit peroxisome proliferator-activated receptor delta/beta in mature osteoclasts. J. Biol. Chem. 275 8126-8132.
232. M. Mano, T. Arakawa, H. Mano, M. Nakagawa, T. Kaneda, H. Kaneko, T. Yamada, K. Miyata, H. Kiyomura, M. Kumegawa and Y. Hakeda (2000) Prostaglandin E2 directly inhibits bone-resorbing activity of isolated mature osteoclasts mainly through the EP4 receptor. Calcif. Tissue Int. 67 85-92.
233. N.P. Martin, E.J. Whalen, M.A. Zamah, K.L. Pierce and R.J. Lefkowitz (2004) PKA-mediated phosphorylation of the beta1-adrenergic receptor promotes Gs/Gi switching. Cell Signal. 16 1397-1403.
234. L. Masi, R. Recenti, S. Silvestri, P. Pinzani, M. Pepi, M. Paglierani, M.L. Brandi and A. Franchi (2007) Expression of cyclooxygenase-2 in osteosarcoma of bone. Appl. Immunohistochem. Mol. Morphol. 15 70-76.
235. K. Matsuo, D.L. Galson, C. Zhao, L. Peng, C. Laplace, K.Z. Wang, M.A. Bachler, H. Amano, H. Aburatani, H. Ishikawa and E.F. Wagner (2004) Nuclear factor of activated T-cells (NFAT) rescues osteoclastogenesis in precursors lacking c-Fos. J. Biol. Chem. 279 26475-26480.
236. A.C. Maurin, P.M. Chavassieux and P.J. Meunier (2005) Expression of PPARgamma and beta/delta in human primary osteoblastic cells: Influence of polyunsaturated fatty acids. Calcif. Tissue Int. 76 385-392.
237. U.R. Mbonye, M. Wada, C.J. Rieke, H.Y. Tang, D.L. DeWitt and W.L. Smith (2006) The 19-amino acid cassette of cyclooxygenase-2 mediates entry of the protein into the endoplasmic reticulum-associated degradation system. J. Biol. Chem. 281 35770-35778.
238. S. Meghji, J.R. Sandy, A.M. Scutt, W. Harvey and M. Harris (1988) Stimulation of bone resorption by lipoxygenase metabolites of arachidonic acid. Prostaglandins 36 139-149.
239. M. Mehrotra, C.B. Alander, O. Voznesensky, L.G. Raisz and C.C. Pilbeam (2004) Fluid shear stress induces cyclooxygenase-2 via activation of protein kinase D in murine primary osteoblasts. J. Bone Miner. Res. 19(S1), S390.
240. M. Mehrotra, M. Saegusa, O. Voznesensky and C. Pilbeam (2006) Role of Cbfa1/Runx2 in the fluid shear stress induction of COX-2 in osteoblasts. Biochem. Biophys. Res. Commun. 341 1225-1230.
241. S. Mehrotra, A. Morimiya, B. Agarwal, R. Konger and S. Badve (2006) Microsomal prostaglandin E2 synthase-1 in breast cancer: A potential target for therapy. J. Pathol. 208 356-363.
242. G.L. Milne, S.C. Sanchez, E.S. Musiek and J.D. Morrow (2007) Quantification of F2-isoprostanes as a biomarker of oxidative stress. Nat. Protoc. 2 221-226.
243. Y. Min and M.A. Crawford (2004) Essential fatty acids. P. Curtis-Prior (Eds) The Eicosanoids West Sussex, England: John Wiley & Sons, Ltd 257-265.
244. Y.K. Min, Y. Rao, Y. Okada, L.G. Raisz and C.C. Pilbeam (1998) Regulation of prostaglandin G/H synthase-2 expression by interleukin-1 in human osteoblast-like cells. J. Bone Miner. Res. 13 1066-1075.
245. Z. MirAfzali, J.R. Leipprandt, J.L. McCracken and D.L. DeWitt (2006) Topography of the prostaglandin endoperoxide H2 synthase-2 in membranes. J. Biol. Chem. 281 28354-28364.
246. C. Miyaura, K. Kenichiro, T. Masuzawa, O. Chaki, Y. Onoe, M. Aoyagi, T. Sasaki, T. Tamura, Y. Koishihara, Y. Ohsugi and T. Suda (1995) Endogenous bone-resorbing factors in estrogen deficiency: Cooperative effects of IL-1 and IL-6. J. Bone Miner. Res. 10 1365-1373.
247. C. Miyaura, M. Inada, T. Suzawa, Y. Sugimoto, F. Ushikubi, A. Ichikawa, S. Narumiya and T. Suda (2000) Impaired bone resorption to prostaglandin E2 in prostaglandin E receptor EP4-knockout mice. J. Biol. Chem. 275 19819-19823.
248. S. Moalic, B. Liagre, J.C. Le Bail and J.L. Beneytout (2001) Dose-dependent modulation of apoptosis and cyclooxygenase-2 expression in human 1547 osteosarcoma cells by NS-398, a selective cyclooxygenase-2 inhibitor. Int. J. Oncol. 18 533-540.
249. P. Montuschi, P.J. Barnes and L.J. Roberts (2004) Isoprostanes: Markers and mediators of oxidative stress. FASEB J. 18 1791-1800.
250. P. Montuschi, P. Barnes and L.J. Roberts (2007) Insights into oxidative stress: The isoprostanes. Curr. Med. Chem. 14 703-717.
251. S.G. Morham, R. Langenbach, C.D. Loftin, H.F. Tiano, N. Vouloumanos, J.C. Jennette, J.F. Mahler, K.D. Kluckman, A. Ledford and C.A. Lee (1995) Prostaglandin synthase 2 gene disruption causes severe renal pathology in the mouse. Cell 83 473-482.
252. Y. Morinaga, N. Fujita, K. Ohishi, Y. Zhang and T. Tsuruo (1998) Suppression of interleukin-11-mediated bone resorption by cyclooxygenases inhibitors. J. Cell Physiol. 175 247-254.
253. J.D. Morrow (2006) The isoprostanes—unique products of arachidonate peroxidation: Their role as mediators of oxidant stress. Curr. Pharm. Des. 12 895-902.
254. D.J. Morton, E.L. Barrett-Connor and D.L. Schneider (1998) Nonsteroidal anti-inflammatory drugs and bone mineral density in older women: The Rancho Bernardo study. J. Bone Miner Res. 13 1924-1931.
255. D. Mozaffarian (2007) JELIS, fish oil, and cardiac events. Lancet 369 1062-1063.
256. D. Mozaffarian and E.B. Rimm (2006) Fish intake, contaminants, and human health: Evaluating the risks and the benefits. JAMA 296 1885-1899.
257. B.H. Mullin, T.D. Spector, C.C. Curtis, G.N. Ong, D.J. Hart, A.J. Hakim, T. Worthy and S.G. Wilson (2007) Polymorphisms in ALOX12, but not ALOX15, are significantly associated with BMD in postmenopausal women. Calcif. Tissue Int. 81 10-17.
258. M.N. Mullins, S.E. Lana, W.S. Dernell, G.K. Ogilvie, S.J. Withrow and E.J. Ehrhart (2004) Cyclooxygenase-2 expression in canine appendicular osteosarcomas. J. Vet. Intern. Med. 18 859-865.
259. M. Murakami and I. Kudo (2004) Recent advances in molecular biology and physiology of the prostaglandin E2-biosynthetic pathway. Prog. Lipid Res. 43 3-35.
260. M. Murakami and I. Kudo (2006) Prostaglandin E synthase: A novel drug target for inflammation and cancer. Curr. Pharm. Des. 12 943-954.
261. M. Murakami, H. Kuwata, Y. Amakasu, S. Shimbara, Y. Nakatani, G. Atsumi and I. Kudo (1997) Prostaglandin E2 amplifies cytosolic phospholipase A2- and cyclooxygenase-2-dependent delayed prostaglandin E2 generation in mouse osteoblastic cells. Enhancement by secretory phospholipase A2. J. Biol. Chem. 272 19891-19897.
262. M. Murakami, H. Naraba, T. Tanioka, N. Semmyo, Y. Nakatani, F. Kojima, T. Ikeda, M. Fueki, A. Ueno and I. Kudo (2000) Regulation of prostaglandin E2 biosynthesis by inducible membrane-associated prostaglandin E2 synthase that acts in concert with cyclooxygenase-2. J. Biol. Chem. 275 32785-32792.
263. M. Murnaghan, G. Li and D.R. Marsh (2006) Nonsteroidal anti-inflammatory drug-induced fracture nonunion: An inhibition of angiogenesis? J. Bone Joint Surg. Am. 88(S3), 140-147.
264. R.C. Murphy, R.C. Bowers, J.D. Dickinson and K.Z. Berry (2004) Perspectives on the biosynthesis and metabolism of eicosanoids. P. Curtis-Prior (Eds) The Eicosanoids West Sussex, England: John Wiley & Sons, Ltd 3-16.
265. E.S. Musiek, L. Gao, G.L. Milne, W. Han, M.B. Everhart, D. Wang, M.G. Backlund, R.N. DuBois, G. Zanoni, G. Vidari, T.S. Blackwell and J.D. Morrow (2005) Cyclopentenone isoprostanes inhibit the inflammatory response in macrophages. J. Biol. Chem. 280 35562-35570.
266. L.K. Myers, S.D. Bhattacharya, P.A. Herring, Z. Xing, S. Goorha, R.A. Smith, S.K. Bhattacharya, L. Carbone, R. Faccio, A.H. Kang and L.R. Ballou (2006) The isozyme-specific effects of cyclooxygenase-deficiency on bone in mice. Bone 39 1048-1052.
267. T. Nagata, K. Kaho, S. Nishikawa, H. Shinohara, Y. Wakano and H. Ishida (1994) Effect of prostaglandin E2 on mineralization of bone nodules formed by fetal rat calvarial cells. Calcif. Tissue Int. 55 451-457.
268. S. Narumiya and G.A. Fitzgerald (2001) Genetic and pharmacological analysis of prostanoid receptor function. J. Clin. Invest. 108 25-30.
269. S. Narumiya, Y. Sugimoto and F. Ushikubi (1999) Prostanoid receptors: Structures, properties, and functions. Physiol. Rev. 79 1193-1226.
270. B.C. Neal, A. Rodgers, T. Clark, H. Gray, I.R. Reid, L. Dunn and S.W. MacMahon (2000) A systematic survey of 13 randomized trials of non-steroidal anti-inflammatory drugs for the prevention of heterotopic bone formation after major hip surgery. Acta Orthop. Scand. 71 122-128.
271. M. Negishi and H. Katoh (2002) Cyclopentenone prostaglandin receptors. Prostaglandins Other Lipid Mediat. 68–69 611-617.
272. R. Newton, J. Seybold, L.M. Kuitert, M. Bergmann and P.J. Barnes (1998) Repression of cyclooxygenase-2 and prostaglandin E2 release by dexamethasone occurs by transcriptional and post-transcriptional mechanisms involving loss of polyadenylated mRNA. J. Biol. Chem. 273 32312-32321.
273. Y. Niki, H. Takaishi, J. Takito, T. Miyamoto, N. Kosaki, H. Matsumoto, Y. Toyama and N. Tada (2007) Administration of cyclooxygenase-2 inhibitor reduces joint inflammation but exacerbates osteopenia in IL-1 alpha transgenic mice due to GM-CSF overproduction. J. Immunol. 179 639-646.
274. O.S. Nilsson and P.E. Persson (1999) Heterotopic bone formation after joint replacement. Curr. Opin. Rheumatol. 11 127-131.
275. N. Nishigaki, M. Negishi and A. Ichikawa (1996) Two Gs-coupled prostaglandin E receptor subtypes, EP2 and EP4, differ in desensitization and sensitivity to the metabolic inactivation of the agonist. Mol. Pharmacol. 50 1031-1037.
276. R.W. Norrdin and M.S. Shih (1988) Systemic effects of prostaglandin E2 on vertebral trabecular remodeling in beagles used in a healing study. Calcif. Tissue Int. 42 363-368.
277. S.M. Norvell, S.M. Ponik, D.K. Bowen, R. Gerard and F.M. Pavalko (2004) Fluid shear stress induction of COX-2 protein and prostaglandin release in cultured MC3T3-E1 osteoblasts does not require intact microfilaments or microtubules. J. Appl. Physiol. 96 957-966.
278. V.F. Norwood, S.G. Morham and O. Smithies (2000) Postnatal development and progression of renal dysplasia in cyclooxygenase-2 null mice. Kidney Int. 58 2291-2300.
279. M.K. O'Banion, H.B. Sadowski, V. Winn and D.A. Young (1991) A serum- and glucorticoid-regulated 4-kilobase mRNA encodes a cyclooxygenase-related protein. J. Biol. Chem. 266 23261-23267.
280. R.J. O'Keefe, P. Tiyapatanaputi, C. Xie, T.F. Li, C. Clark, M.J. Zuscik, D. Chen, H. Drissi, E. Schwarz and X. Zhang (2006) COX-2 has a critical role during incorporation of structural bone allografts. Ann. N. Y. Acad. Sci. 1068 532-542.
281. A. Ogasawara, T. Arakawa, T. Kaneda, T. Takuma, T. Sato, H. Kaneko, M. Kumegawa and Y. Hakeda (2001) Fluid shear stress-induced cyclooxygenase-2 expression is mediated by C/EBP beta, cAMP-response element-binding protein, and AP-1 in osteoblastic MC3T3-E1 cells. J. Biol. Chem. 276 7048-7054.
282. S. Ogawa, T. Urano, T. Hosoi, M. Miyao, S. Hoshino, M. Fujita, M. Shiraki, H. Orimo, Y. Ouchi and S. Inoue (1999) Association of bone mineral density with a polymorphism of the peroxisome proliferator-activated receptor gamma gene: PPARgamma expression in osteoblasts. Biochem. Biophys. Res. Commun. 260 122-126.
283. Y. Okada, S. Tetradis, O. Voznesensky, B.E. Kream, H.R. Herschman, M.M. Hurley and C.C. Pilbeam (1998) AP-1 and CRE sites jointly mediate the induction of prostaglandin G/H synthase-2 promoter activity by basic fibroblast growth factor in osteoblastic MC3T3-E1 cells. Bone 23(S5), S245.
284. Y. Okada, J.A. Lorenzo, A.M. Freeman, M. Tomita, S.G. Morham, L.G. Raisz and C.C. Pilbeam (2000) Prostaglandin G/H synthase-2 is required for maximal formation of osteoclast-like cells in culture. J. Clin. Invest. 105 823-832.
285. Y. Okada, M. Tomita, G. Gronowicz, H. Kawaguchi, J. Sohn, Y. Tanaka, I. Morimoto, T. Nakamura, L. Raisz and C. Pilbeam (2000) Effects of cyclooxygenase-2 gene disruption on osteoblastic function. J. Bone Miner. Res. 15(S1), S217.
286. Y. Okada, O. Voznesensky, H. Herschman, J. Harrison and C. Pilbeam (2000) Identification of multiple cis-acting elements mediating the induction of prostaglandin G.H synthase-2 by phorbol ester in murine osteoblastic cells. J. Cell Biochem. 78 197-209.
287. F. Okamoto, H. Kajiya, H. Fukushima, E. Jimi and K. Okabe (2004) Prostaglandin E2 activates outwardly rectifying Cl– channels via a cAMP-dependent pathway and reduces cell motility in rat osteoclasts. Am. J. Physiol. Cell Physiol. 287 C114-cC124.
288. K. Ono, T. Akatsu, T. Murakami, M. Nishikawa, M. Yamamoto, N. Kugai, K. Motoyoshi and N. Nagata (1998) Important role of EP4, a subtype of prostaglandin (PG) E receptor, in osteoclast-like cell formation from mouse bone marrow cells induced by PGE2. J. Endocrinol 158 R1-rR5. [published erratum appears in J. Endocrinol., 159, 527 (1998)]
289. K. Ono, H. Kaneko, S. Choudhary, C.C. Pilbeam, J.A. Lorenzo, T. Akatsu, N. Kugai and L.G. Raisz (2005) Biphasic effect of prostaglandin E2 on osteoclast formation in spleen cell cultures: Role of the EP2 receptor. J. Bone Miner. Res. 20 23-29.
290. Y. Onoe, C. Miyaura, T. Kaminakayashiki, Y. Nagai, K. Noguchi, Q.R. Chen, H. Seo, H. Ohta, S. Nozawa, I. Kudo and T. Suda (1996) IL-13 and IL-4 inhibit bone resorption by suppressing cyclooxygenase-2-dependent prostaglandin synthesis in osteoblasts. J. Immunol. 156 758-764.
291. R. Pai, B. Soreghan, I.L. Szabo, M. Pavelka, D. Baatar and A.S. Tarnawski (2002) Prostaglandin E2 transactivates EGF receptor: A novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy. Nat. Med. 8 289-293.
292. J.H. Paik, J.H. Ju, J.Y. Lee, M.D. Boudreau and D.H. Hwang (2000) Two opposing effects of non-steroidal anti-inflammatory drugs on the expression of the inducible cyclooxygenase. Mediation through different signaling pathways. J. Biol. Chem. 275 28173-28179.
293. V.M. Paralkar, F. Borovecki, H.Z. Ke, K.O. Cameron, B. Lefker, W.A. Grasser, T.A. Owen, M. Li, P. Silva-Jardine, M. Zhou, R.L. Dunn, F. Dumont, R. Korsmeyer, P. Krasney, T.A. Brown, D. Plowchalk, S. Vukicevic and D.D. Thompson (2003) An EP2 receptor-selective prostaglandin E2 agonist induces bone healing. Proc. Natl. Acad. Sci. USA 100 6736-6740.
294. J.Y. Park, M.H. Pillinger and S.B. Abramson (2006) Prostaglandin E2 synthesis and secretion: The role of PGE2 synthases. Clin. Immunol. 119 229-240.
295. F.M. Pavalko, N.X. Chen, C.H. Turner, D.B. Burr, S. Atkinson, Y.F. Hsieh, J. Qiu and R.L. Duncan (1998) Fluid shear-induced mechanical signaling in MC3T3-E1 osteoblasts requires cytoskeleton-integrin interactions. Am. J. Physiol. 275 C1591-cC1601.
296. F.M. Pavalko, S.M. Norvell, D.B. Burr, C.H. Turner, R.L. Duncan and J.P. Bidwell (2003) A model for mechanotransduction in bone cells: The load-bearing mechanosomes. J. Cell Biochem. 88 104-112.
297. M.J. Pead and L.E. Lanyon (1989) Indomethacin modulation of load-related stimulation of new bone formation in vivo. Calcif. Tissue Int. 45 34-40.
298. M. Peterlik, O. Hoffmann, P. Swetly, K. Klaushofer and K. Koller (1985) Recombinant gamma-interferon inhibits prostaglandin-mediated and parathyroid hormone-induced bone resorption in cultured neonatal mouse calvaria. FEBS Lett. 185 287-290.
299. P.L. Pettersson, S. Thoren and P.J. Jakobsson (2005) Human microsomal prostaglandin E synthase 1: A member of the MAPEG protein superfamily. Methods Enzymol. 401 147-161.
300. C.C. Pilbeam, J. Klein-Nulend and L.G. Raisz (1989) Inhibition by 17β-estradiol of PTH stimulated resorption and prostaglandin production in cultured neonatal mouse calvariae. Biochem. Biophys. Res. Comm. 163 1319-1324.
301. C.C. Pilbeam, H. Kawaguchi, Y. Hakeda, O. Voznesensky, C.B. Alander and L.G. Raisz (1993) Differential regulation of inducible and constitutive prostaglandin endoperoxide synthase in osteoblastic MC3T3-E1 cells. J. Biol. Chem. 268 25643-25649.
302. C.C. Pilbeam, L.G. Raisz, O. Voznesensky, C.B. Alander, B.N. Delman and K. Kawaguchi (1994) Autoregulation of inducible prostaglandin G/H synthase in osteoblastic cells by prostaglandins. J. Bone Miner. Res. 10 406-414.
303. C. Pilbeam, P. Bernecker, J. Harrison, C. Alander, O. Voznesensky, H. Herschman and L. Raisz (1995) Retinoic acid inhibits induction of prostaglandin G/H synthase-2 mRNA and promoter activity in MC3T3-E1 osteoblastic cells. J. Bone Miner. Res. 22(S1), S496.
304. C. Pilbeam, Y. Rao, O. Voznesensky, H. Kawaguchi, C. Alander, L.G. Raisz and H. Herschman (1997) Transforming growth factor-β1 regulation of prostaglandin G/H syntase-2 expression in osteoblastic MC3T3-E1 cells. Endocrinology 138 4672-4682.
305. C.C. Pilbeam, P.M. Fall, C.B. Alander and L.G. Raisz (1997) Differential effects of nonsteroidal anti-inflammatory drugs on constitutive and inducible prostaglandin G/H synthase in cultured bone cells. J. Bone Miner. Res. 12 1198-1203.
306. F.Q. Pirih, T.L. Aghaloo, O. Bezouglaia, J.M. Nervina and S. Tetradis (2005) Parathyroid hormone induces the NR4A family of nuclear orphan receptors in vivo. Biochem. Biophys. Res. Commun. 332 494-503.
307. D. Porte, J. Tuckermann, M. Becker, B. Baumann, S. Teurich, T. Higgins, M.J. Owen, M. Schorpp-Kistner and P. Angel (1999) Both AP-1 and Cbfa1-like factors are required for the induction of interstitial collagenase by parathyroid hormone. Oncogene 18 667-678.
308. R.C. Poulsen and M.C. Kruger (2006) Detrimental effect of eicosapentaenoic acid supplementation on bone following ovariectomy in rats. Prostaglandins Leukot. Essent. Fatty Acids 75 419-427.
309. W.S. Powell (2003) 15-Deoxy-δ12, 14-PGJ2: Endogenous PPARgamma ligand or minor eicosanoid degradation product? J. Clin. Invest. 112 828-830.
310. A. Pozzi, X. Yan, I. ias-Perez, S. Wei, A.N. Hata, R.M. Breyer, J.D. Morrow and J.H. Capdevila (2004) Colon carcinoma cell growth is associated with prostaglandin E2/EP4 receptor-evoked ERK activation. J. Biol. Chem. 279 29797-29804.
311. D. Pratico, J. Rokach, J. Lawson and G.A. Fitzgerald (2004) F2-isoprostanes as indices of lipid peroxidation in inflammatory diseases. Chem. Phys. Lipids 128 165-171.
312. J.Y. Qian, A. Leung, P. Harding and M.C. LaPointe (2006) PGE2 stimulates human brain natriuretic peptide expression via EP4 and p42/44 MAPK. Am. J. Physiol Heart Circ. Physiol. 290 H1740-hH1746.
313. N. Qin, S.P. Zhang, T.L. Reitz, J.M. Mei and C.M. Flores (2005) Cloning, expression, and functional characterization of human cyclooxygenase-1 splicing variants: Evidence for intron 1 retention. J. Pharmacol. Exp. Ther. 315 1298-1305.
314. K.D. Rainsford (2004) Inibitors of eicosanoids. P. Curtis-Prior (Eds) The Eicosanoids West Sussex, England: John Wiley & Sons, Ltd 189-210.
315. L.G. Raisz and T.J. Martin (1983) Prostaglandins in bone and mineral metabolism. W.A. Peck (Eds) Bone and Mineral Research, Annual 2 Amsterdam: Elsevier Science Publishers B.V. 286-310.
316. L.G. Raisz and F.N. Woodiel (2003) Effects of selective prostaglandin EP2 and EP4 receptor agonists on bone resorption and formation in fetal rat organ cultures. Prostaglandins Other Lipid Mediat. 71 287-292.
317. L.G. Raisz, A.L. Sandberg, J.M. Goodson, H.A. Simmons and S.E. Mergenhagen (1974) Complement-dependent stimulation of prostaglandin synthesis and bone resorption. Science 185 789-791.
318. L.G. Raisz, J.Y. Vanderhoek, H.A. Simmons, B.E. Kream and K.C. Nicolaou (1979) Prostaglandin synthesis by fetal rat bone in vitro: Evidence for a role of prostacyclin. Prostaglandins 17 905-914.
319. L.G. Raisz, C.B. Alander and H.A. Simmons (1989) Effects of prostaglandin E3 and eicosapentaenoic acid on rat bone in organ culture. Prostaglandins 37 615-625.
320. L.G. Raisz, C.B. Alander, P.M. Fall and H.A. Simmons (1990) Effects of prostaglandin F2α on bone formation and resorption in cultured neonatal mouse calvariae: Role of prostaglandin E2 production. Endocrinology 126 1076-1079.
321. R. Rajakariar, M.M. Yaqoob and D.W. Gilroy (2006) COX-2 in inflammation and resolution. Mol. Interv. 6 199-207.
322. R. Rao, R. Redha, I. ias-Perez, Y. Su, C. Hao, R. Zent, M.D. Breyer and A. Pozzi (2007) Prostaglandin E2-EP4 receptor promotes endothelial cell migration via ERK activation and angiogenesis in vivo. J. Biol. Chem. 282 16959-16968.
323. S.C. Rawlinson, A.J. El-Haj, S.L. Minter, I.A. Tavares, A. Bennett and L.E. Lanyon (1991) Loading-related increases in prostaglandin production in cores of adult canine cancellous bone in vitro: A role for prostacyclin in adaptive bone remodeling? J. Bone Miner. Res. 6 1345-1351.
324. S.T. Reddy and H.R. Herschman (1997) Prostaglandin synthase-1 and prostaglandin synthase-2 are coupled to distinct phospholipases for the generation of prostaglandin D2 in activated mast cells. J. Biol. Chem. 272 3231-3237.
325. K.M. Reich and J.A. Frangos (1993) Protein kinase C mediates flow-induced prostaglandin E2 production in osteoblasts. Calcif. Tissue Int. 52 62-66.
326. J.B. Richards, L. Joseph, K. Schwartzman, N. Kreiger, A. Tenenhouse and D. Goltzman (2006) The effect of cyclooxygenase-2 inhibitors on bone mineral density: Results from the Canadian Multicentre Osteoporosis Study. Osteoporos. Int. 17 1410-1419.
327. G. Robertson, C. Xie, D. Chen, H. Awad, E.M. Schwarz, R.J. O'Keefe, R.E. Guldberg and X. Zhang (2006) Alteration of femoral bone morphology and density in COX-2−/− mice. Bone 39 767-772.
328. K.L. Roos and D.L. Simmons (2005) Cyclooxygenase variants: The role of alternative splicing. Biochem. Biophys. Res. Commun. 338 62-69.
329. J.B. Rosenquist, A. Ohlin and U.H. Lerner (1996) Cytokine-induced inhibition of bone matrix proteins is not mediated by prostaglandins. Inflamm. Res. 45 457-463.
330. C.A. Rouzer and L.J. Marnett (2005) Structural and functional differences between cyclooxygenases: Fatty acid oxygenases with a critical role in cell signaling. Biochem. Biophys. Res. Commun. 338 34-44.
331. S.O. Rzonca, L.J. Suva, D. Gaddy, D.C. Montague and B. Lecka-Czernik (2004) Bone is a target for the antidiabetic compound rosiglitazone. Endocrinology 145 401-406.
332. M. Saegusa, M. Mehrotra, L.G. Raisz and C.C. Pilbeam (2004) Five minutes of fluid shear stress is sufficient to induce cyclooxygenase-2 in MC3T3–E1 cells. J. Bone Miner. Res. 19(S1), S137.
333. Y. Sakuma, K. Tanaka, M. Suda, Y. Komatsu, A. Yasoda, M. Miura, A. Ozasa, S. Narumiya, Y. Sugimoto, A. Ichikawa, F. Ushikubi and K. Nakao (2000) Impaired bone resorption by lipopolysaccharide in vivo in mice deficient in the prostaglandin E receptor EP4 subtype. Infect. Immun. 68 6819-6825.
334. Y. Sakuma, Z. Li, C.C. Pilbeam, C.B. Alander, D. Chikazu, H. Kawaguchi and L.G. Raisz (2004) Stimulation of cAMP production and cyclooxygenase-2 by prostaglandin E2 and selective prostaglandin receptor agonists in murine osteoblastic cells. Bone 34 827-834.
335. R. Samadfam, M.A. Gallant, M.C. Miousse, J.L. Parent and A.J. de Brum-Fernandes (2006) Implication of prostaglandin receptors in the accumulation of osteoprotegerin in human osteoblast cultures. J. Rheumatol. 33 1167-1175.
336. A.V. Sampey, P. Hutchinson and E.F. Morand (2000) Annexin I and dexamethasone effects on phospholipase and cyclooxygenase activity in human synoviocytes. Mediators. Inflamm. 9 125-132.
337. J.R. Sandy, R.W. Farndale and M.C. Meikle (1993) Recent advances in understanding mechanically induced bone remodeling and their relevance to orthodontic theory and practice. Am. J. Orthod. Dentofacial Orthop. 103 212-222.
338. F.H. Sarkar, S. Adsule, Y. Li and S. Padhye (2007) Back to the future: COX-2 inhibitors for chemoprevention and cancer therapy. Mini. Rev. Med. Chem. 7 599-608.
339. P. Sarrazin, G. Bkaily, R. Hache, C. Patry, R. Dumais, F.A. Rocha and A.J. de Brum-Fernandes (2001) Characterization of the prostaglandin receptors in human osteoblasts in culture. Prostaglandins Leukot. Essent. Fatty Acids 64 203-210.
340. P. Sarrazin, J.A. Hackett, I. Fortier, M.A. Gallant and A. de Brum-Fernandes (2004) Role of EP3 and EP4 prostaglandin receptors in reorganization of the cytoskeleton in mature human osteoclasts. J. Rheumatol. 31 1598-1606.
341. K. Sato, Y. Fujii, K. Kasono, M. Saji, T. Tsushima and K. Shizume (1986) Stimulation of prostaglandin E2 and bone resorption by recombinant human interleukin 1 alpha in fetal long bone. Biochem. Biophys. Res. Comm. 618 624.
342. T. Sato, I. Morita, K. Sakaguchi, K.I. Nakahama, W.L. Smith, D.L. DeWitt and S.I. Murota (1996) Involvement of prostaglandin endoperoxide H synthase-2 in osteoclast-like cell formation induced by interleukin-1 beta. J. Bone Miner. Res. 11 392-400.
343. T. Sato, I. Morita and S. Murota (1997) Prostaglandin E2 mediates parathyroid hormone induced osteoclast formation by cyclic AMP independent mechanism. Adv. Exp. Med. Biol. 407 383-386.
344. H. Sawada, M. Murakami, A. Enomoto, S. Shimbara and I. Kudo (1999) Regulation of type V phospholipase A2 expression and function by proinflammatory stimuli. Eur. J. Biochem. 263 826-835.
345. R.H. Schaloske and E.A. Dennis (2006) The phospholipase A2 superfamily and its group numbering system. Biochim. Biophys. Acta. 1761 1246-1259.
346. J.U. Scher and M.H. Pillinger (2005) 15d-PGJ2: The anti-inflammatory prostaglandin? Clin. Immunol. 114 100-109.
347. J.M. Schwab, N. Chiang, M. Arita and C.N. Serhan (2007) Resolvin E1 and protectin D1 activate inflammation-resolution programmes. Nature 447 869-874.
348. A. Scutt and P. Bertram (1995) Bone marrow cells are targets for the anabolic actions of prostaglandin E2 on bone: Induction of a transition from nonadherent to adherent osteoblast precursors. J. Bone Miner. Res. 10 474-487.
349. E. Segi, Y. Sugimoto, A. Yamasaki, Y. Aze, H. Oida, T. Nishimura, T. Murata, T. Matsuoka, F. Ushikubi, M. Hirose, T. Tanaka, N. Yoshida, S. Narumiya and A. Ichikawa (1998) Patent ductus arteriosus and neonatal death in prostaglandin receptor EP4-deficient mice. Biochem. Biophys. Res. Commun. 246 7-12.
350. C.N. Serhan (2007) Resolution phase of inflammation: Novel endogenous anti-inflammatory and proresolving lipid mediators and pathways. Annu. Rev. Immunol. 25 101-137.
351. C.N. Serhan, A. Jain, S. Marleau, C. Clish, A. Kantarci, B. Behbehani, S.P. Colgan, G.L. Stahl, A. Merched, N.A. Petasis, L. Chan and T.E. Van Dyke (2003) Reduced inflammation and tissue damage in transgenic rabbits overexpressing 15-lipoxygenase and endogenous anti-inflammatory lipid mediators. J. Immunol. 171 6856-6865.
352. S.S. Shaftel, J.A. Olschowka, S.D. Hurley, A.H. Moore and M.K. O'Banion (2003) COX-3: A splice variant of cyclooxygenase-1 in mouse neural tissue and cells. Brain Res. Mol. Brain Res. 119 213-215.
353. K. Shahedi, S. Lindstrom, S.L. Zheng, F. Wiklund, J. Adolfsson, J. Sun, K. ugustsson-Balter, B.L. Chang, H.O. Adami, W. Liu, H. Gronberg and J. Xu (2006) Genetic variation in the COX-2 gene and the association with prostate cancer risk. Int. J. Cancer. 119 668-672.
354. J. Shao, S.B. Lee, H. Guo, B.M. Evers and H. Sheng (2003) Prostaglandin E2 stimulates the growth of colon cancer cells via induction of amphiregulin. Cancer Res. 63 5218-5223.
355. J. Shao, C. Jung, C. Liu and H. Sheng (2005) Prostaglandin E2 stimulates the beta-catenin/T cell factor-dependent transcription in colon cancer. J. Biol. Chem. 280 26565-26572.
356. S.K. Shenoy and R.J. Lefkowitz (2005) Seven-transmembrane receptor signaling through beta-arrestin. Sci. STKE 2005 cm 10.
357. D.M. Shinar and G.A. Rodan (1990) Biphasic effects of transforming growth factor-beta on the production of osteoclast-like cells in mouse bone marrow cultures: The role of prostaglandins in the generation of these cells. Endocrinology 126 3153-3158.
358. M. Shoji, N. Tanabe, N. Mitsui, H. Tanaka, N. Suzuki, O. Takeichi, A. Sugaya and M. Maeno (2006) Lipopolysaccharide stimulates the production of prostaglandin E2 and the receptor Ep4 in osteoblasts. Life Sci. 78 2012-2018.
359. D.L. Simmons, R.M. Botting and T. Hla (2004) Cyclooxygenase isozymes: The biology of prostaglandin synthesis and inhibition. Pharmacol. Rev. 56 387-437.
360. A.M. Simon and J.P. O'Connor (2007) Dose and time-dependent effects of cyclooxygenase-2 inhibition on fracture-healing. J. Bone Joint Surg. Am. 89 500-511.
361. A.M. Simon, M.B. Manigrasso and J.P. O'Connor (2002) Cyclo-oxygenase 2 function is essential for bone fracture healing. J. Bone Miner. Res. 17 963-976.
362. W.L. Smith (1989) The eicosanoids and their biochemical mechanisms of action. Biochem. J. 259 315-324.
363. W.L. Smith and R. Langenbach (2001) Why there are two cyclooxygenase isozymes. J. Clin. Invest. 107 1491-1495.
364. W.L. Smith and I. Song (2002) The enzymology of prostaglandin endoperoxide H synthases-1 and -2. Prostaglandins Other Lipid Mediat. 68–69 115-128.
365. W.L. Smith, D.L. DeWitt and R.M. Garavito (2000) Cyclooxygenases: Structural, cellular, and molecular biology. Annu. Rev. Biochem. 69 145-182.
366. J.A. Snipes, B. Kis, G.S. Shelness, J.A. Hewett and D.W. Busija (2005) Cloning and characterization of cyclooxygenase-1b (putative cyclooxygenase-3) in rat. J. Pharmacol. Exp. Ther. 313 668-676.
367. A.S. Sonmez, M. Birincioglu, M.K. Ozer, R. Kutlu and C.J. Chuong (1999) Effects of misoprostol on bone loss in ovariectomized rats. Prostaglandins Other Lipid Mediat. 57 113-118.
368. A.G. Spencer, J.W. Woods, T. Arakawa, I.I. Singer and W.L. Smith (1998) Subcellular localization of prostaglandin endoperoxide H synthases-1 and -2 by immunoelectron microscopy. J. Biol. Chem. 273 9886-9893.
369. A.G. Spencer, E. Thuresson, J.C. Otto, I. Song, T. Smith, D.L. DeWitt, R.M. Garavito and W.L. Smith (1999) The membrane binding domains of prostaglandin endoperoxide H synthases 1 and 2. Peptide mapping and mutational analysis. J. Biol. Chem. 274 32936-32942.
370. S. Srinivasan and T.S. Gross (2000) Canalicular fluid flow induced by bending of a long bone. Med. Eng Phys. 22 127-133.
371. P.H. Stern (2006) The calcineurin-NFAT pathway and bone: Intriguing new findings. Mol. Interv. 6 193-196.
372. P.H. Stern, N.S. Krieger, R.A. Nissenson, R.D. Williams, M.E. Winkler, R. Derynck and G.J. Strewler (1985) Human transforming growth factor-alpha stimulates bone resorption in vitro. J. Clin. Invest. 76 2016-2019.
373. P.J. Stork and T.J. Dillon (2005) Multiple roles of Rap1 in hematopoietic cells: Complementary versus antagonistic functions. Blood 106 2952-2961.
374. P.J. Stork and J.M. Schmitt (2002) Crosstalk between cAMP and MAP kinase signaling in the regulation of cell proliferation. Trends Cell Biol. 12 258-266.
375. D.S. Straus and C.K. Glass (2001) Cyclopentenone prostaglandins: New insights on biological activities and cellular targets. Med. Res. Rev. 21 185-210.
376. M. Suda, K. Tanaka, K. Natsui, T. Usui, I. Tanaka, M. Fukushima, C. Shigeno, J. Konishi, S. Narumiya, A. Ichikawa and N. Nakao (1996) Prostaglandin E receptor subtypes in mouse osteoblastic cell line. Endocrinology 137 1698-1705.
377. K. Suda, N. Udagawa, N. Sato, M. Takami, K. Itoh, J.T. Woo, N. Takahashi and K. Nagai (2004) Suppression of osteoprotegerin expression by prostaglandin E2 is crucially involved in lipopolysaccharide-induced osteoclast formation. J. Immunol. 172 2504-2510.
378. Y. Sugimoto and S. Narumiya (2007) Prostaglandin E receptors. J. Biol. Chem. 282 11613-11617.
379. K. Sumitani, T. Kawata, T. Yoshimoto, S. Yamamoto and M. Kumegawa (1989) Fatty acid cyclo-oxygenase activity stimulated by transforming growth factor β in mouse osteoblastic cells (MC3T3–E1). Arch. Biochem. Biophys. 270 588-595.
380. D. Sun, A. Krishnan, K. Zaman, R. Lawrence, A. Bhattacharya and G. Fernandes (2003) Dietary n-3 fatty acids decrease osteoclastogenesis and loss of bone mass in ovariectomized mice. J. Bone Miner. Res. 18 1206-1216.
381. Y. Sun, J. Huang, Y. Xiang, M. Bastepe, H. Juppner, B.K. Kobilka, J.J. Zhang and X.Y. Huang (2007) Dosage-dependent switch from G protein-coupled to G protein-independent signaling by a GPCR. EMBO J. 26 53-64.
382. I. Suponitzky and M. Weinreb (1998) Differential effects of systemic prostaglandin E2 on bone mass in rat long bones and calvariae. J. Endocrinol. 156 51-57.
383. T. Suzawa, C. Miyaura, M. Inada, T. Maruyama, Y. Sugimoto, F. Ushikubi, A. Ichikawa, S. Narumiya and T. Suda (2000) The role of prostaglandin E receptor subtypes (EP1, EP2, EP3, and EP4) in bone resorption: An analysis using specific agonists for the respective EPs. Endocrinology 141 1554-1559.
384. D.C. Swinney, A.Y. Mak, J. Barnett and C.S. Ramesha (1997) Differential allosteric regulation of prostaglandin H synthase 1 and 2 by arachidonic acid. J. Biol. Chem. 272 12393-12398.
385. V.L. Sylvia, T.F. Del Jr., R.R. Hardin, D.D. Dean, B.D. Boyan and Z. Schwartz (2001) Characterization of PGE2 receptors (EP) and their role as mediators of 1alpha, 25-(OH)2D3 effects on growth zone chondrocytes. J. Steroid Biochem. Mol. Biol. 78 261-274.
386. H. Tai, C. Miyaura, C.C. Pilbeam, T. Tamura, Y. Ohsugi, Y. Koishihara, N. Kubodera, H. Kawaguchi, L.G. Raisz and T. Suda (1997) Transcriptional induction of cyclooxygenase-2 in osteoblasts is involved in interleukin-6-induced osteoclast formation. Endocrinology 138 2372-2379.
387. H.H. Tai, C.M. Ensor, M. Tong, H. Zhou and F. Yan (2002) Prostaglandin catabolizing enzymes. Prostaglandins Other Lipid Mediat. 68–69 483-493.
388. H.H. Tai, H. Cho, M. Tong and Y. Ding (2006) NAD+-linked 15-hydroxyprostaglandin dehydrogenase: Structure and biological functions. Curr. Pharm. Des. 12 955-962.
389. Y. Takahashi, Y. Taketani, T. Endo, S. Yamamoto and M. Kumegawa (1994) Studies on the induction of cyclooxygenase isozymes by various prostaglandins in mouse osteoblastic cell line with reference to signal transduction pathways. Biochim. Biophys. Acta 1212 217-224.
390. I. Take, Y. Kobayashi, Y. Yamamoto, H. Tsuboi, T. Ochi, S. Uematsu, N. Okafuji, S. Kurihara, N. Udagawa and N. Takahashi (2005) Prostaglandin E2 strongly inhibits human osteoclast formation. Endocrinology 146 5204-5214.
391. G. Talosi, M. Katona, K. Racz, E. Kertesz, B. Onozo and S. Turi (2004) Prostaglandin E1 treatment in patent ductus arteriosus dependent congenital heart defects. J. Perinat. Med. 32 368-374.
392. W. Tan, J. Wu, X. Zhang, Y. Guo, J. Liu, T. Sun, B. Zhang, D. Zhao, M. Yang, D. Yu and D. Lin (2007) Associations of functional polymorphisms in cyclooxygenase-2 and platelet 12-lipoxygenase with risk of occurrence and advanced disease status of colorectal cancer. Carcinogenesis 28 1197-1201.
393. T. Tanabe and N. Tohnai (2002) Cyclooxygenase isozymes and their gene structures and expression. Prostaglandins Other Lipid Mediat. 68–69 95-114.
394. M. Tanaka, A. Sakai, S. Uchida, S. Tanaka, M. Nagashima, T. Katayama, K. Yamaguchi and T. Nakamura (2004) Prostaglandin E2 receptor (EP4) selective agonist (ONO-4819.CD) accelerates bone repair of femoral cortex after drill-hole injury associated with local upregulation of bone turnover in mature rats. Bone 34 940-948.
395. T. Tanioka, Y. Nakatani, N. Semmyo, M. Murakami and I. Kudo (2000) Molecular identification of cytosolic prostaglandin E2 synthase that is functionally coupled with cyclooxygenase-1 in immediate prostaglandin E2 biosynthesis. J. Biol. Chem. 275 32775-32782.
396. A.H.J. Tashjian, E.L. Hohmann, H.N. Antoniades and L. Levine (1982) Platelet-derived growth factor stimulates bone resorption via a prostaglandin-mediated mechanism. Endocrinology 111 118-124.
397. A.H.J. Tashjian, E.F. Voelkel, M. Lazzaro, F.R. Singer, A.B. Roberts, R. Derynck, M.E. Winkler and L. Levine (1985) Alpha and beta human transforming growth factors stimulate prostaglandin production and bone resorption in cultured mouse calvaria. Proc. Natl. Acad. Sci. USA 82 4535-4538.
398. A.H.J. Tashjian, E.F. Voelkel, M. Lazzaro, D. Goad, T. Bosma and L. Levine (1987) Tumor necrosis factor-alpha (cachectin) stimulates bone resorption in mouse calvaria via a prostaglandin-mediated mechanism. Endocrinology 120 2029-2036.
399. S. Tetradis, C.C. Pilbeam, Y. Liu and B.E. Kream (1996) Parathyroid hormone induces prostaglandin G/H synthase-2 expression by a cyclic adenosine 3′, 5′-monophosphate-mediated pathway in the murine osteoblastic cell line MC3T3-E1. Endocrinology 137 5435-5440.
400. S. Tetradis, C.C. Pilbeam, Y. Liu, H.R. Herschman and B.E. Kream (1997) Parathyroid hormone increases prostaglandin G/H synthase-2 transcription by a cyclic adenosine 3′, 5′-monophosphate-mediated pathway in murine osteoblastic MC3T3–E1 cells. Endocrinology 138 3594-3600.
401. K. Thorsen, A.O. Kristoffersson, U.H. Lerner and R.P. Lorentzon (1997) In situ microdialysis in bone tissue: Stimulation of prostaglandin E2 release by weight-bearing mechanical loading. J. Clin. Invest. 98 2446-2449.
402. Y. Tintut, F. Parhami, A. Tsingotjidou, S. Tetradis, M. Territo and L.L. Demer (2002) 8-Isoprostaglandin E2 enhances receptor-activated NFkappa B ligand (RANKL)-dependent osteoclastic potential of marrow hematopoietic precursors via the cAMP pathway. J. Biol. Chem. 277 14221-14226.
403. M. Tomita, J. Harrison, Y. Okada, O. Voznesensky, L. Raisz and C. Pilbeam (1998) Tumor necrosis factor-α stimulation of prostaglanding G/H synthase-2 promoter activity in osteoblastic MC3T3-E1 cells requires an intact AP-1 site. Bone 23(S5), S354.
404. M. Tomita, X. Li, Y. Okada, F.N. Woodiel, R.N. Young, C.C. Pilbeam and L.G. Raisz (2002) Effects of selective prostaglandin EP4 receptor antagonist on osteoclast formation and bone resorption in vitro. Bone 30 159-163.
405. K. Traianedes, M.R. Dallas, I.R. Garrett, G.R. Mundy and L.F. Bonewald (1998) 5-Lipoxygenase metabolites inhibit bone formation in vitro. Endocrinology 139 3178-3184.
406. T.M. Trebble, M.A. Stroud, S.A. Wootton, P.C. Calder, D.R. Fine, M.A. Mullee, C. Moniz and N.K. Arden (2005) High-dose fish oil and antioxidants in Crohn's disease and the response of bone turnover: A randomised controlled trial. Br. J. Nutr. 94 253-261.
407. C.E. Trebino, J.L. Stock, C.P. Gibbons, B.M. Naiman, T.S. Wachtmann, J.P. Umland, K. Pandher, J.M. Lapointe, S. Saha, M.L. Roach, D. Carter, N.A. Thomas, B.A. Durtschi, J.D. McNeish, J.E. Hambor, P.J. Jakobsson, T.J. Carty, J.R. Perez and L.P. Audoly (2003) Impaired inflammatory and pain responses in mice lacking an inducible prostaglandin E synthase. Proc. Natl. Acad. Sci. USA 100 9044-9049.
408. O.C. Trifan and T. Hla (2003) Cyclooxygenase-2 modulates cellular growth and promotes tumorigenesis. J. Cell Mol. Med. 7 207-222.
409. C. Tsatsanis, A. Androulidaki, M. Venihaki and A.N. Margioris (2006) Signalling networks regulating cyclooxygenase-2. Int. J. Biochem. Cell Biol. 38 1654-1661.
410. K. Tsukii, N. Shima, S. Mochizuki, K. Yamaguchi, M. Kinosaki, K. Yano, O. Shibata, N. Udagawa, H. Yasuda, T. Suda and K. Higashio (1998) Osteoclast differentiation factor mediates an essential signal for bone resorption induced by 1 alpha, 25–dihydroxyvitamin D3, prostaglandin E2, or parathyroid hormone in the microenvironment of bone [In Process Citation]. Biochem. Biophys. Res. Commun. 246 337-341.
411. C.H. Turner and F.M. Pavalko (1998) Mechanotransduction and functional response of the skeleton to physical stress: The mechanisms and mechanics of bone adaptation. J. Orthop. Sci. 3 346-355.
412. C.H. Turner, M.R. Forwood and M.W. Otter (1994) Mechanotransduction in bone: Do bone cells act as sensors of fluid flow? FASEB J. 8 875-878.
413. K. Ueda, A. Saito, H. Nakano, M. Aoshima, M. Yokota, R. Muraoka and T. Iwaya (1980) Cortical hyperostosis following long-term administration of prostaglandin E1 in infants with cyanotic congenital heart disease. J. Pediatr. 97 834-836.
414. T. Urano, M. Shiraki, M. Fujita, T. Hosoi, H. Orimo, Y. Ouchi and S. Inoue (2005) Association of a single nucleotide polymorphism in the lipoxygenase ALOX15 5′-flanking region (−5229G/A) with bone mineral density. J. Bone Miner. Metab. 23 226-230.
415. R. Urciuoli, T.A. Cantisani, M. CarliniI, M. Giuglietti and F.M. Botti (2004) Prostaglandin E1 for treatment of erectile dysfunction. Cochrane Database. Syst. Rev. CD001784.
416. K. Vaddadi (2004) Essential fatty acids: Eicosanoid precursors in the treatment of Huntington's disease. P. Curtis-Prior (Eds) The Eicosanoids West Sussex, England: John Wiley & Sons, Ltd 499-506.
417. W.A. van der Donk, A.L. Tsai and R.J. Kulmacz (2002) The cyclooxygenase reaction mechanism. Biochemistry 41 15451-15458.
418. E.F. Voelkel, A.H. Tashjian Jr. and L. Levine (1980) Cyclooxygenase products of arachidonic acid metabolism by mouse bone in organ culture. Biochim. Biophys. Acta. 620 418-428.
419. U. von Euler (1936) On specific vasodilating and plain muscle stimulating substances from accessory genital glands in man and certain animals (prostaglandin and vesiglandin). J. Physiol. 88 213-234.
420. M. Wada, C.J. Delong, Y.H. Hong, C.J. Rieke, I. Song, R.S. Sidhu, C. Yuan, M. Warnock, A.H. Schmaier, C. Yokoyama, E.M. Smyth, S.J. Wilson, G.A. Fitzgerald, R.M. Garavito, D.X. Sui, J.W. Regan and W.L. Smith (2007) Enzymes and receptors of prostaglandin pathways with arachidonic acid- vs. eicosapentaenoic acid-derived substrates and products. J. Biol. Chem. 282 22254-22266.
421. S. Wadhwa, S. Choudhary, M. Voznesensky, M. Epstein, L. Raisz and C. Pilbeam (2002) Fluid flow induces COX-2 expression in MC3T3-E1 osteoblasts via a PKA signaling pathway. Biochem. Biophys. Res Commun. 297 46-51.
422. S. Wadhwa, S.L. Godwin, D.R. Peterson, M.A. Epstein, L.G. Raisz and C.C. Pilbeam (2002) Fluid flow induction of cyclo-oxygenase 2 gene expression in osteoblasts is dependent on an extracellular signal-regulated kinase signaling pathway. J. Bone Miner. Res. 17 266-274.
423. D.J. Wadleigh and H.R. Herschman (1999) Transcriptional regulation of the cyclooxygenase-2 gene by diverse ligands in murine osteoblasts. Biochem. Biophys. Res. Commun. 264 865-870.
424. D.J. Wadleigh, S.T. Reddy, E. Kopp, S. Ghosh and H.R. Herschman (2000) Transcriptional activation of the cyclooxygenase-2 gene in endotoxin-treated RAW 264.7 macrophages. J. Biol. Chem. 275 6259-6266.
425. D. Wang and R.N. DuBois (2006) Prostaglandins and cancer. Gut 55 115-122.
426. D. Wang and R.N. DuBois (2007) Inflammatory mediators and nuclear receptor signaling in colorectal cancer. Cell Cycle 6 682-685.
427. J. Wang, K. Yamamoto, Y. Sugimoto, A. Ichikawa and S. Yamamoto (1999) Induction of prostaglandin I2 receptor by tumor necrosis factor alpha in osteoblastic MC3T3-E1 cells. Biochim. Biophys. Acta. 1441 69-76.
428. D. Wang, H. Wang, Q. Shi, S. Katkuri, W. Walhi, B. Desvergne, S.K. Das, S.K. Dey and R.N. DuBois (2004) Prostaglandin E2 promotes colorectal adenoma growth via transactivation of the nuclear peroxisome proliferator-activated receptor delta. Cancer Cell 6 285-295.
429. H. Wang, W.G. Ma, L. Tejada, H. Zhang, J.D. Morrow, S.K. Das and S.K. Dey (2004) Rescue of female infertility from the loss of cyclooxygenase-2 by compensatory up-regulation of cyclooxygenase-1 is a function of genetic makeup. J. Biol. Chem. 279 10649-10658.
430. D. Wang, F.G. Buchanan, H. Wang, S.K. Dey and R.N. DuBois (2005) Prostaglandin E2 enhances intestinal adenoma growth via activation of the Ras-mitogen-activated protein kinase cascade. Cancer Res. 65 1822-1829.
431. M. Wang, A.M. Zukas, Y. Hui, E. Ricciotti, E. Pure and G.A. Fitzgerald (2006) Deletion of microsomal prostaglandin E synthase-1 augments prostacyclin and retards atherogenesis. Proc. Natl. Acad. Sci. USA 103 14507-14512.
432. Z. Wang, T.J. Dillon, V. Pokala, S. Mishra, K. Labudda, B. Hunter and P.J. Stork (2006) Rap1-mediated activation of extracellular signal-regulated kinases by cyclic AMP is dependent on the mode of Rap1 activation. Mol. Cell Biol. 26 2130-2145.
433. M.R. Wani, K. Fuller, N.S. Kim, Y. Choi and T. Chambers (1999) Prostaglandin E2 cooperates with TRANCE in osteoclast induction from hemopoietic precursors: Synergistic activation of differentiation, cell spreading, and fusion. Endocrinology 140 1927-1935.
434. K. Watanabe, K. Kurihara, Y. Tokunaga and O. Hayaishi (1997) Two types of microsomal prostaglandin E synthase: Glutathione-dependent and -independent prostaglandin E synthases. Biochem. Biophys. Res. Commun. 235 148-152.
435. B.A. Watkins, Y. Li and M.F. Seifert (2006) Dietary ratio of n-6/n-3 PUFAs and docosahexaenoic acid: Actions on bone mineral and serum biomarkers in ovariectomized rats. J. Nutr. Biochem. 17 282-289.
436. S. Weinbaum, S.C. Cowin and Y. Zeng (1994) A model for the excitation of osteocytes by mechanical loading- induced bone fluid shear stresses. J. Biomechanics 27 339-360.
437. M. Weinreb, I. Suponitzky and S. Keila (1997) Systemic administration of an anabolic dose of PGE2 in young rats increases the osteogenic capacity of bone marrow. Bone 20 521-526.
438. L.A. Weiss, E. Barrett-Connor and M.D. von (2005) Ratio of n-6 to n-3 fatty acids and bone mineral density in older adults: the Rancho Bernardo Study. Am. J. Clin. Nutr. 81 934-938.
439. N.H. Wilson (2004) Synthetic eicosanoids. P. Curtis-Prior (Eds) The Eicosanoids West Sussex, England: John Wiley & Sons, Ltd 69-94.
440. M.M. Winslow, M. Pan, M. Starbuck, E.M. Gallo, L. Deng, G. Karsenty and G.R. Crabtree (2006) Calcineurin/NFAT signaling in osteoblasts regulates bone mass. Dev. Cell. 10 771-782.
441. A.P. Wolffe and D. Pruss (1996) Targeting chromatin disruption: Transcription regulators that acetylate histones. Cell 84 817-819.
442. E. Wong, C. DeLuca, C. Boily, S. Charleson, W. Cromlish, D. Denis, S. Kargman, B.P. Kennedy, M. Ouellet, K. Skorey, G.P. O'Neill, P.J. Vickers and D. Riendeau (1997) Characterization of autocrine inducible prostaglandin H synthase-2 (PGHS-2) in human osteosarcoma cells. Inflamm. Res. 46 51-59.
443. F.N. Woodiel, P.M. Fall and L.G. Raisz (1996) Anabolic effects of prostaglandins in cultured fetal rat calvariae: Structure-activity relations and signal transduction pathway. J. Bone Miner. Res. 11 1249-1255.
444. G. Xiao, D. Jiang, P. Thomas, M.D. Benson, K. Guan, G. Karsenty and R.T. Franceschi (2000) MAPK pathways activate and phosphorylate the osteoblast-specific transcription factor, Cbfa1. J. Biol. Chem. 275 4453-4459.
445. W.L. Xie, J.G. Chipman, D.L. Robertson, R.L. Erikson and D.L. Simmons (1991) Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc. Natl. Acad. Sci. USA 88 2692-2696.
446. Q. Xu, T. Konta, A. Furusu, K. Nakayama, J. Lucio-Cazana, L.G. Fine and M. Kitamura (2002) Transcriptional induction of mitogen-activated protein kinase phosphatase 1 by retinoids. Selective roles of nuclear receptors and contribution to the antiapoptotic effect. J. Biol. Chem. 277 41693-41700.
447. M. Xu, S. Choudhary, Q. Gao, O.S. Voznesensky, D.J. Adams, L.G. Raisz and C.C. Pilbeam (2005) Effects of genetic background on phenotype of cyclooxygenase-2 knockout mice. J. Bone Miner. Res. 20(S1), S182.
448. M. Xu, S. Choudhary, D. Goltzman, F. Ledgard, D. Adams, G. Gronowicz, B. Koczon-Jaremko, L. Raisz and C. Pilbeam (2005) Do cyclooxygenase knockout mice have primary hyperparathyroidism? Endocrinology 146 1843-1853.
449. M. Xu, Q. Gao, O. Voznesensky, S. Choudhary, D. Adams, L. Raisz and C. Pilbeam (2006) Cyclooxygenase-2 knockout does not prevent bone loss after ovariectomy. J. Bone Miner. Res. 21(S1), S413.
450. Z. Xu, S. Choudhary, O. Voznesensky, M. Mehrotra, M. Woodard, M. Hansen, H. Herschman and C. Pilbeam (2006) Overexpression of COX-2 in human osteosarcoma cells decreases proliferation and increases apoptosis. Cancer Res. 66 6657-6664.
451. M. Xu, Q. Gao, O. Voznesensky, S. Choudhary, V. Diaz-Doran, L. Raisz and C. Pilbeam (2007) Intermittent PTH has increased anabolic effects in cyclooxygenase-2 knockout mice. J. Bone Miner. Res. 22(S1), S66.
452. Z. Xu, S. Choudhary, Y. Okada, O. Voznesensky, C. Alander, L. Raisz and C. Pilbeam (2007) Cyclooxygenase-2 gene disruption promotes proliferation of murine calvarial osteoblasts in vitro. Bone 41 68-76.
453. K. Yamamoto, T. Arakawa, N. Ueda and S. Yamamoto (1995) Transcriptional roles of nuclear factor kappa B and nuclear factor- interleukin-6 in the tumor necrosis factor alpha-dependent induction of cyclooxygenase-2 in MC3T3-E1 cells. J. Biol. Chem. 270 31315-31320.
454. M. Yan, R.M. Rerko, P. Platzer, D. Dawson, J. Willis, M. Tong, E. Lawrence, J. Lutterbaugh, S. Lu, J.K. Willson, G. Luo, J. Hensold, H.H. Tai, K. Wilson and S.D. Markowitz (2004) 15–Hydroxyprostaglandin dehydrogenase, a COX-2 oncogene antagonist, is a TGF-beta-induced suppressor of human gastrointestinal cancers. Proc. Natl. Acad. Sci. USA 101 17468-17473.
455. L. Yasar, A.S. Sonmez, N. Utku, J. Ozcan, Z. Cebi, K. Savan and N. Sut (2006) Effect of misoprostol on bone mineral density in women with postmenopausal osteoporosis. Prostaglandins Other Lipid Mediat. 79 199-205.
456. H. Yin, L. Gao, H.H. Tai, L.J. Murphey, N.A. Porter and J.D. Morrow (2007) Urinary prostaglandin F2alpha is generated from the isoprostane pathway and not the cyclooxygenase in humans. J. Biol. Chem. 282 329-336.
457. C. Yokoyama and T. Tanabe (1989) Cloning of human gene encoding prostaglandin endoperoxide synthase and primary structure of the enzyme. Biochem. Biophys. Res. Commun. 165 888-894.
458. K. Yoshida, H. Oida, T. Kobayashi, T. Maruyama, M. Tanaka, T. Katayama, K. Yamaguchi, E. Segi, T. Tsuboyama, M. Matsushita, K. Ito, Y. Ito, Y. Sugimoto, F. Ushikubi, S. Ohuchida, K. Kondo, T. Nakamura and S. Narumiya (2002) Stimulation of bone formation and prevention of bone loss by prostaglandin E EP4 receptor activation. Proc. Natl. Acad. Sci. USA 99 4580-4585.
459. Y. Yu, J. Fan, X.S. Chen, D. Wang, A.J. Klein-Szanto, R.L. Campbell, G.A. Fitzgerald and C.D. Funk (2006) Genetic model of selective COX2 inhibition reveals novel heterodimer signaling. Nat. Med. 12 699-704.
460. Y. Yu, J. Fan, Y. Hui, C.A. Rouzer, L.J. Marnett, A.J. Klein-Szanto, G.A. Fitzgerald and C.D. Funk (2007) Targeted cyclooxygenase gene (ptgs) exchange reveals discriminant isoform functionality. J. Biol. Chem. 282 1498-1506.
461. C. Yuan, C.J. Rieke, G. Rimon, B.A. Wingerd and W.L. Smith (2006) Partnering between monomers of cyclooxygenase-2 homodimers. Proc. Natl. Acad. Sci. USA 103 6142-6147.
462. P. Zhan, C. Alander, H. Kaneko, C.C. Pilbeam, Y. Guan, Y. Zhang, M.D. Breyer and L.G. Raisz (2005) Effect of deletion of the prostaglandin EP4 receptor on stimulation of calcium release from cultured mouse calvariae: Impaired responsiveness in heterozygotes. Prostaglandins Other Lipid Mediat. 78 19-26.
463. J. Zhang, S. Goorha, R. Raghow and L.R. Ballou (2002) The tissue-specific, compensatory expression of cyclooxygenase-1 and −2 in transgenic mice. Prostaglandins Other Lipid Mediat. 67 121-135.
464. X. Zhang, E.M. Schwarz, D.A. Young, J.E. Puzas, R.N. Rosier and R.J. O'Keefe (2002) Cyclooxygenase-2 regulates mesenchymal cell differentiation into the osteoblast lineage and is critically involved in bone repair. J. Clin. Invest. 109 1405-1415.
465. X. Zhang, X. Miao, W. Tan, B. Ning, Z. Liu, Y. Hong, W. Song, Y. Guo, X. Zhang, Y. Shen, B. Qiang, F.F. Kadlubar and D. Lin (2005) Identification of functional genetic variants in cyclooxygenase-2 and their association with risk of esophageal cancer. Gastroenterology 129 565-576.
466. B. Zingarelli and J.A. Cook (2005) Peroxisome proliferator-activated receptor-gamma is a new therapeutic target in sepsis and inflammation. Shock 23 393-399.